{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["breast cancer", "drug delivery", "molecular mechanisms", "nanoparticles", "natural products", "phytomedicine"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "34880614", "DateCompleted": {"Year": "2021", "Month": "12", "Day": "10"}, "DateRevised": {"Year": "2023", "Month": "11", "Day": "02"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "12", "Day": "02"}], "Language": ["eng"], "ELocationID": ["10.2147/IJN.S328135"], "Journal": {"ISSN": "1178-2013", "JournalIssue": {"Volume": "16", "PubDate": {"Year": "2021"}}, "Title": "International journal of nanomedicine", "ISOAbbreviation": "Int J Nanomedicine"}, "ArticleTitle": "Drug Delivery of Natural Products Through Nanocarriers for Effective Breast Cancer Therapy: A Comprehensive Review of Literature.", "Pagination": {"StartPage": "7891", "EndPage": "7941", "MedlinePgn": "7891-7941"}, "Abstract": {"AbstractText": ["Despite recent advances in the diagnosis and treatment of breast cancer (BC), it remains a global health issue affecting millions of women annually. Poor prognosis in BC patients is often linked to drug resistance as well as the lack of effective therapeutic options for metastatic and triple-negative BC. In response to these unmet needs, extensive research efforts have been devoted to exploring the anti-BC potentials of natural products owing to their multi-target mechanisms of action and good safety profiles. Various medicinal plant extracts/essential oils and natural bioactive compounds have demonstrated anti-cancer activities in preclinical BC models. Despite the promising preclinical results, however, the clinical translation of natural products has often been hindered by their poor stability, aqueous solubility and bioavailability. There have been attempts to overcome these limitations, particularly via the use of nano-based drug delivery systems (NDDSs). This review highlights the tumour targeting mechanisms of NDDSs, the advantages and disadvantages of the major classes of NDDSs and their current clinical status in BC treatment. Besides, it also discusses the proposed anti-BC mechanisms and nanoformulations of nine medicinal plants' extracts/essential oils and nine natural bioactive compounds; selected via the screening of various scientific databases, including PubMed, Scopus and Google Scholar, based on the following keywords: \"Natural Product AND Nanoparticle AND Breast Cancer\". Overall, these nanoformulations exhibit improved anti-cancer efficacy against preclinical BC models, with some demonstrating biocompatibility with normal cell lines and mouse models. Further clinical studies are, however, warranted to ascertain their efficacy and biocompatibility in humans."], "CopyrightInformation": "\u00a9 2021 Yap et al."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Health Sciences, Universiti Kuala Lumpur Royal College of Medicine Perak, Ipoh, Perak, 30450, Malaysia."}], "LastName": "Yap", "ForeName": "Kah Min", "Initials": "KM"}, {"Identifier": ["0000-0002-3022-6137"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Health Sciences, Universiti Kuala Lumpur Royal College of Medicine Perak, Ipoh, Perak, 30450, Malaysia."}], "LastName": "Sekar", "ForeName": "Mahendran", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Pharmacy, AIMST University, Kedah, 08100, Malaysia."}], "LastName": "Fuloria", "ForeName": "Shivkanya", "Initials": "S"}, {"Identifier": ["0000-0001-5574-8049"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Centre for Virus and Vaccine Research, School of Medical and Life Sciences, Sunway University, Selangor, 47500, Malaysia."}, {"Identifier": [], "Affiliation": "Department of Biological Sciences, School of Medical and Life Sciences, Sunway University, Selangor, 47500, Malaysia."}], "LastName": "Wu", "ForeName": "Yuan Seng", "Initials": "YS"}, {"Identifier": ["0000-0001-6470-3651"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmacy, Monash University Malaysia, Bandar Sunway, Selangor Darul Ehsan, 47500, Malaysia."}], "LastName": "Gan", "ForeName": "Siew Hua", "Initials": "SH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Pharmacy and Health Sciences, Universiti Kuala Lumpur Royal College of Medicine Perak, Ipoh, Perak, 30450, Malaysia."}], "LastName": "Mat Rani", "ForeName": "Nur Najihah Izzati", "Initials": "NNI"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Medicine, Bioscience and Nursing, MAHSA University, Selangor, 42610, Malaysia."}], "LastName": "Subramaniyan", "ForeName": "Vetriselvan", "Initials": "V"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutics, Sinhgad Technical Education Society's, Sinhgad Institute of Pharmacy, Narhe, Pune, 411041, India."}], "LastName": "Kokare", "ForeName": "Chandrakant", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Health Sciences, Universiti Kuala Lumpur Royal College of Medicine Perak, Ipoh, Perak, 30450, Malaysia."}], "LastName": "Lum", "ForeName": "Pei Teng", "Initials": "PT"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutics, College of Pharmacy, King Khalid University (KKU), Asir-Abha, 61421, Saudi Arabia."}], "LastName": "Begum", "ForeName": "M Yasmin", "Initials": "MY"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, Sri Adichunchanagiri College of Pharmacy, Adichunchanagiri University, Mandya, Karnataka, 571418, India."}], "LastName": "Mani", "ForeName": "Shankar", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy, National University of Science and Technology, Muscat, 130, Oman."}], "LastName": "Meenakshi", "ForeName": "Dhanalekshmi Unnikrishnan", "Initials": "DU"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Applied Sciences, AIMST University, Kedah, 08100, Malaysia."}], "LastName": "Sathasivam", "ForeName": "Kathiresan V", "Initials": "KV"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Pharmacy, AIMST University, Kedah, 08100, Malaysia."}], "LastName": "Fuloria", "ForeName": "Neeraj Kumar", "Initials": "NK"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "New Zealand", "MedlineTA": "Int J Nanomedicine", "NlmUniqueID": "101263847", "ISSNLinking": "1176-9114"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Biological Products"}, {"RegistryNumber": "0", "NameOfSubstance": "Nanoparticle Drug Delivery System"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Biological Products"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Breast Neoplasms"}, {"QualifierName": [], "DescriptorName": "Drug Delivery Systems"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Nanoparticle Drug Delivery System"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}], "CoiStatement": "The authors have no conflicts of interest associated with this work nor the publication. There was also no significant financial support for this work."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Sun YS, Zhao Z, Yang ZN, et al. Risk factors and preventions of breast cancer. Int J Biol Sci. 2017;13(11):1387\u20131397. doi:10.7150/ijbs.21635", "ArticleIdList": ["10.7150/ijbs.21635", "PMC5715522", "29209143"]}, {"Citation": "Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u2013249. doi:10.3322/caac.21660", "ArticleIdList": ["10.3322/caac.21660", "33538338"]}, {"Citation": "Wang L. Early diagnosis of breast cancer. Sensors. 2017;17(7):1572. doi:10.3390/s17071572", "ArticleIdList": ["10.3390/s17071572", "PMC5539491", "28678153"]}, {"Citation": "Hattori M, Iwata H. Advances in treatment and care in metastatic breast cancer (MBC): are there MBC patients who are curable? Chin Clin Oncol. 2018;7(3):23. doi:10.21037/cco.2018.05.01", "ArticleIdList": ["10.21037/cco.2018.05.01", "29860850"]}, {"Citation": "Jin X, Mu P. Targeting breast cancer metastasis. Breast Cancer Basic Clin Res. 2015;9(Suppl 1):23\u201334. doi:10.4137/BCBCR.S25460", "ArticleIdList": ["10.4137/BCBCR.S25460", "PMC4559199", "26380552"]}, {"Citation": "Peart O. Metastatic breast cancer. Radiol Technol. 2017;88(5):519M\u2013539M.", "ArticleIdList": ["28500107"]}, {"Citation": "Dai X, Li T, Bai Z, et al. Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res. 2015;5(10):2929\u20132943.", "ArticleIdList": ["PMC4656721", "26693050"]}, {"Citation": "Yersal O, Barutca S. Biological subtypes of breast cancer: prognostic and therapeutic implications. World J Clin Oncol. 2014;5(3):412\u2013424. doi:10.5306/wjco.v5.i3.412", "ArticleIdList": ["10.5306/wjco.v5.i3.412", "PMC4127612", "25114856"]}, {"Citation": "Mehanna J, Haddad FG, Eid R, Lambertini M, Kourie HR. Triple-negative breast cancer: current perspective on the evolving therapeutic landscape. Int J Womens Health. 2019;11:431\u2013437. doi:10.2147/IJWH.S178349", "ArticleIdList": ["10.2147/IJWH.S178349", "PMC6682754", "31447592"]}, {"Citation": "Talluri SV, Pindiprolu SKSS, Chintamaneni PK, Tummala S, Nandha Kumar S. RAGE receptor targeted bioconjuguate lipid nanoparticles of diallyl disulfide for improved apoptotic activity in triple negative breast cancer: in vitro studies. Artif Cells Nanomedicine Biotechnol. 2017;46(2):387\u2013397. doi:10.1080/21691401.2017.1313267", "ArticleIdList": ["10.1080/21691401.2017.1313267", "28415882"]}, {"Citation": "Cheung KL. Treatment strategies and survival outcomes in breast cancer. Cancers (Basel). 2020;12(3):735. doi:10.3390/cancers12030735", "ArticleIdList": ["10.3390/cancers12030735", "PMC7140050", "32244985"]}, {"Citation": "Waks AG, Winer EP. Breast cancer treatment: a review. J Am Med Assoc. 2019;321(3):288\u2013300. doi:10.1001/jama.2018.19323", "ArticleIdList": ["10.1001/jama.2018.19323", "30667505"]}, {"Citation": "Anampa J, Makower D, Sparano JA. Progress in adjuvant chemotherapy for breast cancer: an overview. BMC Med. 2015;13:1\u201313. doi:10.1186/s12916-015-0439-8", "ArticleIdList": ["10.1186/s12916-015-0439-8", "PMC4538915", "26278220"]}, {"Citation": "Luque-Bolivar A, P\u00e9rez-Mora E, Villegas VE, Rond\u00f3n-Lagos M. Resistance and overcoming resistance in breast cancer. Breast Cancer Targets Ther. 2020;12:211\u2013229. doi:10.2147/BCTT.S270799", "ArticleIdList": ["10.2147/BCTT.S270799", "PMC7666993", "33204149"]}, {"Citation": "Dias DA, Urban S, Roessner U. A historical overview of natural products in drug discovery. Metabolites. 2012;2(2):303\u2013336. doi:10.3390/metabo2020303", "ArticleIdList": ["10.3390/metabo2020303", "PMC3901206", "24957513"]}, {"Citation": "Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT. Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov. 2021;20(3):200\u2013216. doi:10.1038/s41573-020-00114-z", "ArticleIdList": ["10.1038/s41573-020-00114-z", "PMC7841765", "33510482"]}, {"Citation": "Cragg GM, Pezzuto JM. Natural products as a vital source for the discovery of cancer chemotherapeutic and chemopreventive agents. Med Princ Pract. 2016;25(Suppl 2):41\u201359. doi:10.1159/000443404", "ArticleIdList": ["10.1159/000443404", "PMC5588531", "26679767"]}, {"Citation": "Beutler JA. Natural products as a foundation for drug discovery. Curr Protoc Pharmacol. 2009;46:9\u201311. doi:10.1002/0471141755.ph0911s46", "ArticleIdList": ["10.1002/0471141755.ph0911s46", "PMC2813068", "20161632"]}, {"Citation": "Kooti W, Servatyari K, Behzadifar M, et al. Effective medicinal plant in cancer treatment, part 2: review study. J Evid Based Complementary Altern Med. 2017;22(4):982\u2013995. doi:10.1177/2156587217696927", "ArticleIdList": ["10.1177/2156587217696927", "PMC5871268", "28359161"]}, {"Citation": "Kapinova A, Kubatka P, Golubnitschaja O, et al. Dietary phytochemicals in breast cancer research: anticancer effects and potential utility for effective chemoprevention. Environ Health Prev Med. 2018;23:1\u201318. doi:10.1186/s12199-018-0724-1", "ArticleIdList": ["10.1186/s12199-018-0724-1", "PMC6085646", "30092754"]}, {"Citation": "Rezadoost MH, Kumleh HH, Ghasempour A. Cytotoxicity and apoptosis induction in breast cancer, skin cancer and glioblastoma cells by plant extracts. Mol Biol Rep. 2019;46(5):5131\u20135142. doi:10.1007/s11033-019-04970-w", "ArticleIdList": ["10.1007/s11033-019-04970-w", "31317456"]}, {"Citation": "Gautam N, Mantha AK, Mittal S. Essential oils and their constituents as anticancer agents: a mechanistic view. Biomed Res Int. 2014;2014:154106. doi:10.1155/2014/154106", "ArticleIdList": ["10.1155/2014/154106", "PMC4070586", "25003106"]}, {"Citation": "Bayala B, Bassole IH, Scifo R, et al. Anticancer activity of essential oils and their chemical components - a review. Am J Cancer Res. 2014;4(6):591\u2013607.", "ArticleIdList": ["PMC4266698", "25520854"]}, {"Citation": "Sharifi-Rad J, Sureda A, Tenore GC, et al. Biological activities of essential oils: from plant chemoecology to traditional healing systems. Molecules. 2017;22(1):70. doi:10.3390/molecules22010070", "ArticleIdList": ["10.3390/molecules22010070", "PMC6155610", "28045446"]}, {"Citation": "Turek C, Stintzing FC. Stability of essential oils: a review. Compr Rev Food Sci Food Saf. 2013;12(1):40\u201353. doi:10.1111/1541-4337.12006", "ArticleIdList": ["10.1111/1541-4337.12006"]}, {"Citation": "Aung TN, Qu Z, Kortschak RD, Adelson DL. Understanding the effectiveness of natural compound mixtures in cancer through their molecular mode of action. Int J Mol Sci. 2017;18(3):656. doi:10.3390/ijms18030656", "ArticleIdList": ["10.3390/ijms18030656", "PMC5372668", "28304343"]}, {"Citation": "Kesarwani K, Gupta R, Mukerjee A. Bioavailability enhancers of herbal origin: an overview. Asian Pac J Trop Biomed. 2013;3(4):253\u2013266. doi:10.1016/S2221-1691(13)60060-X", "ArticleIdList": ["10.1016/S2221-1691(13)60060-X", "PMC3634921", "23620848"]}, {"Citation": "Sulaiman GM, Waheeb HM, Jabir MS, Khazaal SH, Dewir YH, Naidoo Y. Hesperidin loaded on gold nanoparticles as a drug delivery system for a successful biocompatible, anti-cancer, anti-inflammatory and phagocytosis inducer model. Sci Rep. 2020;10(1):9362. doi:10.1038/s41598-020-66419-6", "ArticleIdList": ["10.1038/s41598-020-66419-6", "PMC7283242", "32518242"]}, {"Citation": "Jabir M, Sahib UI, Taqi Z, et al. Linalool-loaded glutathione-modified gold nanoparticles conjugated with CALNN peptide as apoptosis inducer and NF-\u03baB translocation inhibitor in SKOV-3 cell line. Int J Nanomedicine. 2020;2020(15):9025\u20139047. doi:10.2147/IJN.S276714", "ArticleIdList": ["10.2147/IJN.S276714", "PMC7680166", "33235450"]}, {"Citation": "Mohammed HA, Sulaiman GM, Anwar SS, et al. Quercetin against MCF7 and CAL51 breast cancer cell lines: apoptosis, gene expression and cytotoxicity of nano-quercetin. Nanomedicine. 2021;16(22):1937\u20131961. doi:10.2217/nnm-2021-0070", "ArticleIdList": ["10.2217/nnm-2021-0070", "34431317"]}, {"Citation": "Li J, Ge Z, Toh K, et al. Enzymatically transformable polymersome-based nanotherapeutics to eliminate minimal relapsable cancer. Adv Mater. 2021;e2105254. doi:10.1002/adma.202105254", "ArticleIdList": ["10.1002/adma.202105254", "34622509"]}, {"Citation": "Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018;16(1):71. doi:10.1186/s12951-018-0392-8", "ArticleIdList": ["10.1186/s12951-018-0392-8", "PMC6145203", "30231877"]}, {"Citation": "Attia MF, Anton N, Wallyn J, Omran Z, Vandamme TF. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. J Pharm Pharmacol. 2019;71(8):1185\u20131198. doi:10.1111/jphp.13098", "ArticleIdList": ["10.1111/jphp.13098", "31049986"]}, {"Citation": "Ho BN, Pfeffer CM, Singh ATK. Update on nanotechnology-based drug delivery systems in cancer treatment. Anticancer Res. 2017;37(11):5975\u20135981. doi:10.21873/anticanres.12044", "ArticleIdList": ["10.21873/anticanres.12044", "29061776"]}, {"Citation": "Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60(15):1615\u20131626. doi:10.1016/j.addr.2008.08.005", "ArticleIdList": ["10.1016/j.addr.2008.08.005", "18840489"]}, {"Citation": "Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun. 2018;9(1):1410. doi:10.1038/s41467-018-03705-y", "ArticleIdList": ["10.1038/s41467-018-03705-y", "PMC5897557", "29650952"]}, {"Citation": "Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in cancer. Vasc Health Risk Manag. 2006;2(3):213\u2013219. doi:10.2147/vhrm.2006.2.3.213", "ArticleIdList": ["10.2147/vhrm.2006.2.3.213", "PMC1993983", "17326328"]}, {"Citation": "Kalyane D, Raval N, Maheshwari R, Tambe V, Kalia K, Tekade RK. Employment of enhanced permeability and retention effect (EPR): nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer. Mater Sci Eng C. 2019;98:1252\u20131276. doi:10.1016/j.msec.2019.01.066", "ArticleIdList": ["10.1016/j.msec.2019.01.066", "30813007"]}, {"Citation": "Colone M, Calcabrini A, Stringaro A. Drug delivery systems of natural products in oncology. Molecules. 2020;25(19):4560. doi:10.3390/molecules25194560", "ArticleIdList": ["10.3390/molecules25194560", "PMC7582809", "33036240"]}, {"Citation": "Uthaman S, Huh KM, Park IK. Tumor microenvironment-responsive nanoparticles for cancer theragnostic applications. Biomater Res. 2018;22:1\u201311. doi:10.1186/s40824-018-0132-z", "ArticleIdList": ["10.1186/s40824-018-0132-z", "PMC6108142", "30155269"]}, {"Citation": "Sakurai Y, Akita H, Harashima H. Targeting tumor endothelial cells with nanoparticles. Int J Mol Sci. 2019;20(23):5819. doi:10.3390/ijms20235819", "ArticleIdList": ["10.3390/ijms20235819", "PMC6928777", "31756900"]}, {"Citation": "Liu CG, Han YH, Kankala RK, Wang SB, Chen AZ. Subcellular performance of nanoparticles in cancer therapy. Int J Nanomedicine. 2020;15:675\u2013704. doi:10.2147/IJN.S226186", "ArticleIdList": ["10.2147/IJN.S226186", "PMC7008395", "32103936"]}, {"Citation": "Markman JL, Rekechenetskiy A, Holler E, Ljubimova JY. Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv Drug Deliv Rev. 2013;65(13\u201314):1866\u20131879. doi:10.1016/j.addr.2013.09.019", "ArticleIdList": ["10.1016/j.addr.2013.09.019", "PMC5812459", "24120656"]}, {"Citation": "Wu D, Si M, Xue HY, Wong HL. Nanomedicine applications in the treatment of breast cancer: current state of the art. Int J Nanomedicine. 2017;12:5879\u20135892. doi:10.2147/IJN.S123437", "ArticleIdList": ["10.2147/IJN.S123437", "PMC5566389", "28860754"]}, {"Citation": "Rauti R, Musto M, Bosi S, Prato M, Ballerini L. Properties and behavior of carbon nanomaterials when interfacing neuronal cells: how far have we come? Carbon N Y. 2018;143430\u2013143446. doi:10.1016/j.carbon.2018.11.026", "ArticleIdList": ["10.1016/j.carbon.2018.11.026"]}, {"Citation": "Cha C, Shin SR, Annabi N, Dokmeci MR, Khademhosseini A. Carbon-based nanomaterials: multi-functional materials for biomedical engineering. ACS Nano. 2013;7(4):2891\u20132897. doi:10.1021/nn401196a", "ArticleIdList": ["10.1021/nn401196a", "PMC3648999", "23560817"]}, {"Citation": "Maiti D, Tong X, Mou X, Yang K. Carbon-based nanomaterials for biomedical applications: a recent study. Front Pharmacol. 2018;9:1401. doi:10.3389/fphar.2018.01401", "ArticleIdList": ["10.3389/fphar.2018.01401", "PMC6421398", "30914959"]}, {"Citation": "Garriga R, Herrero-Continente T, Palos M, et al. Toxicity of carbon nanomaterials and their potential application as drug delivery systems: in vitro studies in Caco-2 and MCF-7 cell lines. Nanomaterials. 2020;10(8):1617. doi:10.3390/nano10081617", "ArticleIdList": ["10.3390/nano10081617", "PMC7466705", "32824730"]}, {"Citation": "Yang Q, Wang XD, Chen J, et al. A clinical study on regional lymphatic chemotherapy using an activated carbon nanoparticle-epirubicin in patients with breast cancer. Tumor Biol. 2012;33(6):2341\u20132348. doi:10.1007/s13277-012-0496-y", "ArticleIdList": ["10.1007/s13277-012-0496-y", "22948779"]}, {"Citation": "Madaan K, Kumar S, Poonia N, Lather V, Pandita D. Dendrimers in drug delivery and targeting: drug-dendrimer interactions and toxicity issues. J Pharm Bioallied Sci. 2014;6(3):139\u2013150. doi:10.4103/0975-7406.130965", "ArticleIdList": ["10.4103/0975-7406.130965", "PMC4097927", "25035633"]}, {"Citation": "Abbasi E, Aval SF, Akbarzadeh A, et al. Dendrimers: synthesis, applications, and properties. Nanoscale Res Lett. 2014;9(1):247. doi:10.1186/1556-276X-9-247", "ArticleIdList": ["10.1186/1556-276X-9-247", "PMC4074873", "24994950"]}, {"Citation": "Chis AA, Dobrea C, Morgovan C, et al. Applications and limitations of dendrimers in biomedicine. Molecules. 2020;25(17):3982. doi:10.3390/molecules25173982", "ArticleIdList": ["10.3390/molecules25173982", "PMC7504821", "32882920"]}, {"Citation": "Chauhan AS. Dendrimers for drug delivery. Molecules. 2018;23(4):938. doi:10.3390/molecules23040938", "ArticleIdList": ["10.3390/molecules23040938", "PMC6017392", "29670005"]}, {"Citation": "Wolinsky JB, Grinstaff MW. Therapeutic and diagnostic applications of dendrimers for cancer treatment. Adv Drug Deliv Rev. 2008;60(9):1037\u20131055. doi:10.1016/j.addr.2008.02.012", "ArticleIdList": ["10.1016/j.addr.2008.02.012", "18448187"]}, {"Citation": "Palmerston Mendes L, Pan J, Torchilin VP. Dendrimers as nanocarriers for nucleic acid and drug delivery in cancer therapy. Molecules. 2017;22(9):1401. doi:10.3390/molecules22091401", "ArticleIdList": ["10.3390/molecules22091401", "PMC5600151", "28832535"]}, {"Citation": "Janaszewska A, Lazniewska J, Trzepi\u0144ski P, Marcinkowska M, Klajnert-Maculewicz B. Cytotoxicity of dendrimers. Biomolecules. 2019;9(8):330. doi:10.3390/biom9080330", "ArticleIdList": ["10.3390/biom9080330", "PMC6723213", "31374911"]}, {"Citation": "Starpharma. DEP\u00ae docetaxel positive Phase 1 results; Phase 2 commences; 2017. Available from: https://starpharma.com/news/339. Accessed August\n2, 2021."}, {"Citation": "Starpharma. DEP\u00ae irinotecan phase 2 commences after positive phase 1 results; 2020. Available from: https://www.starpharma.com/news/story/dep-irinotecan-phase-2-commences-after-positive-phase-1-results. Accessed August\n2, 2021."}, {"Citation": "Arias JL, Clares B, Morales ME, Gallardo V, Ruiz MA. Lipid-based drug delivery systems for cancer treatment. Curr Drug Targets. 2011;12(8):1151\u20131165. doi:10.2174/138945011795906570", "ArticleIdList": ["10.2174/138945011795906570", "21443475"]}, {"Citation": "Garc\u00eda-Pinel B, Porras-Alcal\u00e1 C, Ortega-Rodr\u00edguez A, et al. Lipid-based nanoparticles: application and recent advances in cancer treatment. Nanomaterials. 2019;9(4):638. doi:10.3390/nano9040638", "ArticleIdList": ["10.3390/nano9040638", "PMC6523119", "31010180"]}, {"Citation": "Yingchoncharoen P, Kalinowski DS, Richardson DR. Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come. Pharmacol Rev. 2016;68(3):701\u2013787. doi:10.1124/pr.115.012070", "ArticleIdList": ["10.1124/pr.115.012070", "PMC4931871", "27363439"]}, {"Citation": "Habib S, Singh M. Recent advances in lipid-based nanosystems for gemcitabine and gemcitabine\u2013combination therapy. Nanomaterials. 2021;11(3):597. doi:10.3390/nano11030597", "ArticleIdList": ["10.3390/nano11030597", "PMC7997169", "33673636"]}, {"Citation": "Barenholz Y. Doxil\u00ae\u2013the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117\u2013134. doi:10.1016/j.jconrel.2012.03.020", "ArticleIdList": ["10.1016/j.jconrel.2012.03.020", "22484195"]}, {"Citation": "Ventola CL. Progress in nanomedicine: approved and investigational nanodrugs. Pharm Ther. 2017;42(12):742\u2013755.", "ArticleIdList": ["PMC5720487", "29234213"]}, {"Citation": "Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9(2):12. doi:10.3390/pharmaceutics9020012", "ArticleIdList": ["10.3390/pharmaceutics9020012", "PMC5489929", "28346375"]}, {"Citation": "Salehi B, Selamoglu Z, Mileski KS, et al. Liposomal cytarabine as cancer therapy: from chemistry to medicine. Biomolecules. 2019;9(12):773. doi:10.3390/biom9120773", "ArticleIdList": ["10.3390/biom9120773", "PMC6995526", "31771220"]}, {"Citation": "Le Rhun E, Wallet J, Mailliez A, et al. Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer. Neuro Oncol. 2020;22(4):524\u2013538. doi:10.1093/neuonc/noz201", "ArticleIdList": ["10.1093/neuonc/noz201", "PMC7158648", "31637444"]}, {"Citation": "Chen S, Hanning S, Falconer J, Locke M, Wen J. Recent advances in non-ionic surfactant vesicles (niosomes): fabrication, characterization, pharmaceutical and cosmetic applications. Eur J Pharm Biopharm. 2019;144:18\u201339. doi:10.1016/j.ejpb.2019.08.015", "ArticleIdList": ["10.1016/j.ejpb.2019.08.015", "31446046"]}, {"Citation": "Bartelds R, Nematollahi MH, Pols T, et al. Niosomes, an alternative for liposomal delivery. PLoS One. 2018;13(4):e0194179. doi:10.1371/journal.pone.0194179", "ArticleIdList": ["10.1371/journal.pone.0194179", "PMC5896898", "29649223"]}, {"Citation": "Kanaani L, Javadi I, Ebrahimifar M, Ebrahimi Shahmabadi H, Akbarzadeh Khiyav A, Mehrdiba T. Effects of cisplatin-loaded niosomal nanoparticles on BT-20 human breast carcinoma cells. Asian Pacific J Cancer Prev. 2017;18(2):365\u2013368. doi:10.22034/APJCP.2017.18.2.365", "ArticleIdList": ["10.22034/APJCP.2017.18.2.365", "PMC5454728", "28345332"]}, {"Citation": "Nowroozi F, Dadashzadeh S, Soleimanjahi H, et al. Theranostic niosomes for direct intratumoral injection: marked enhancement in tumor retention and anticancer efficacy. Nanomedicine. 2018;13(17):2201\u20132219. doi:10.2217/nnm-2018-0091", "ArticleIdList": ["10.2217/nnm-2018-0091", "29993311"]}, {"Citation": "Salem HF, Kharshoum RM, Abo El-Ela FI, Amr Gamal F, Abdellatif KRA. Evaluation and optimization of pH-responsive niosomes as a carrier for efficient treatment of breast cancer. Drug Deliv Transl Res. 2018;8(3):633\u2013644. doi:10.1007/s13346-018-0499-3", "ArticleIdList": ["10.1007/s13346-018-0499-3", "29488171"]}, {"Citation": "Duan Y, Dhar A, Patel C, et al. A brief review on solid lipid nanoparticles: part and parcel of contemporary drug delivery systems. RSC Adv. 2020;10:26777\u201326791. doi:10.1039/D0RA03491F", "ArticleIdList": ["10.1039/D0RA03491F", "PMC9055574", "35515778"]}, {"Citation": "Kang KW, Chun MK, Kim O, et al. Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy. Nanomedicine. 2010;6(2):210\u2013213. doi:10.1016/j.nano.2009.12.006", "ArticleIdList": ["10.1016/j.nano.2009.12.006", "20060074"]}, {"Citation": "Garg NK, Singh B, Jain A, et al. Fucose decorated solid-lipid nanocarriers mediate efficient delivery of methotrexate in breast cancer therapeutics. Colloids Surfaces B Biointerfaces. 2016;146:114\u2013126. doi:10.1016/j.colsurfb.2016.05.051", "ArticleIdList": ["10.1016/j.colsurfb.2016.05.051", "27268228"]}, {"Citation": "Xu W, Bae EJ, Lee MK. Enhanced anticancer activity and intracellular uptake of paclitaxel-containing solid lipid nanoparticles in multidrug-resistant breast cancer cells. Int J Nanomedicine. 2018;13:7549\u20137563. doi:10.2147/IJN.S182621", "ArticleIdList": ["10.2147/IJN.S182621", "PMC6241869", "30532538"]}, {"Citation": "Guney Eskiler G, Cecener G, Dikmen G, Egeli U, Tunca B. Solid lipid nanoparticles: reversal of tamoxifen resistance in breast cancer. Eur J Pharm Sci. 2018;120:73\u201388. doi:10.1016/j.ejps.2018.04.040", "ArticleIdList": ["10.1016/j.ejps.2018.04.040", "29719240"]}, {"Citation": "Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages. Res Pharm Sci. 2018;13(4):288\u2013303. doi:10.4103/1735-5362.235156", "ArticleIdList": ["10.4103/1735-5362.235156", "PMC6040163", "30065762"]}, {"Citation": "Pandey P, Dureja H. Recent patents on polymeric nanoparticles for cancer therapy. Recent Pat Nanotechnol. 2018;12(2):155\u2013169. doi:10.2174/1872210512666180327120648", "ArticleIdList": ["10.2174/1872210512666180327120648", "29589551"]}, {"Citation": "Dadwal A, Baldi A, Kumar Narang R. Nanoparticles as carriers for drug delivery in cancer. Nanomed Biotechnol. 2018;46:295\u2013305. doi:10.1080/21691401.2018.1457039", "ArticleIdList": ["10.1080/21691401.2018.1457039", "30043651"]}, {"Citation": "Gutierrez Cisneros C, Bloemen V, Mignon A. Synthetic, natural, and semisynthetic polymer carriers for controlled nitric oxide release in dermal applications: a review. Polymers. 2021;13(5):760. doi:10.3390/polym13050760", "ArticleIdList": ["10.3390/polym13050760", "PMC7957520", "33671032"]}, {"Citation": "Sithole MN, Choonara YE, Du Toit LC, Kumar P, Pillay V. A review of semi-synthetic biopolymer complexes: modified polysaccharide nano-carriers for enhancement of oral drug bioavailability. Pharm Dev Technol. 2017;22(2):283\u2013295. doi:10.1080/10837450.2016.1212882", "ArticleIdList": ["10.1080/10837450.2016.1212882", "27470222"]}, {"Citation": "Wong KH, Lu A, Chen X, Yang Z. Natural ingredient-based polymeric nanoparticles for cancer treatment. Molecules. 2020;25(16):3620. doi:10.3390/molecules25163620", "ArticleIdList": ["10.3390/molecules25163620", "PMC7463484", "32784890"]}, {"Citation": "Avramovi\u0107 N, Mandi\u0107 B, Savi\u0107-Radojevi\u0107 A, Simi\u0107 T. Polymeric nanocarriers of drug delivery systems in cancer therapy. Pharmaceutics. 2020;12(4):298. doi:10.3390/pharmaceutics12040298", "ArticleIdList": ["10.3390/pharmaceutics12040298", "PMC7238125", "32218326"]}, {"Citation": "Liu Z, Jiao Y, Wang Y, Zhou C, Zhang Z. Polysaccharides-based nanoparticles as drug delivery systems. Adv Drug Deliv Rev. 2008;60(15):1650\u20131662. doi:10.1016/j.addr.2008.09.001", "ArticleIdList": ["10.1016/j.addr.2008.09.001", "18848591"]}, {"Citation": "El-Say KM, El-Sawy HS. Polymeric nanoparticles: promising platform for drug delivery. Int J Pharm. 2017;528(1\u20132):675\u2013691. doi:10.1016/j.ijpharm.2017.06.052", "ArticleIdList": ["10.1016/j.ijpharm.2017.06.052", "28629982"]}, {"Citation": "Park IH, Sohn JH, Kim SB, et al. An open-label, randomized, parallel, phase III trial evaluating the efficacy and safety of polymeric micelle-formulated paclitaxel compared to conventional Cremophor EL-based paclitaxel for recurrent or metastatic HER2-negative breast cancer. Cancer Res Treat. 2017;49(3):569\u2013577. doi:10.4143/crt.2016.289", "ArticleIdList": ["10.4143/crt.2016.289", "PMC5512366", "27618821"]}, {"Citation": "Sevastre A-S, Horescu C, Baloi SC, et al. Benefits of nanomedicine for therapeutic intervention in malignant diseases. Coatings. 2019;9:628. doi:10.3390/coatings9100628", "ArticleIdList": ["10.3390/coatings9100628"]}, {"Citation": "Bernabeu E, Cagel M, Lagomarsino E, Moretton M, Chiappetta DA. Paclitaxel: what has been done and the challenges remain ahead. Int J Pharm. 2017;526(1\u20132):474\u2013495. doi:10.1016/j.ijpharm.2017.05.016", "ArticleIdList": ["10.1016/j.ijpharm.2017.05.016", "28501439"]}, {"Citation": "Northfelt DW, Allred JB, Liu H, et al.; North Central Cancer Treatment Group. Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer. Am J Clin Oncol. 2014;37(2):167\u2013171. doi:10.1097/COC.0b013e31826e0550", "ArticleIdList": ["10.1097/COC.0b013e31826e0550", "PMC3593738", "23211220"]}, {"Citation": "Sandra F, Khaliq NU, Sunna A, Care A. Developing protein-based nanoparticles as versatile delivery systems for cancer therapy and imaging. Nanomaterials. 2019;9(9):1329. doi:10.3390/nano9091329", "ArticleIdList": ["10.3390/nano9091329", "PMC6781024", "31527483"]}, {"Citation": "Diaz D, Care A, Sunna A. Bioengineering strategies for protein-based nanoparticles. Genes. 2018;9(7):370. doi:10.3390/genes9070370", "ArticleIdList": ["10.3390/genes9070370", "PMC6071185", "30041491"]}, {"Citation": "Hong S, Choi DW, Kim HN, Park CG, Lee W, Park HH. Protein-based nanoparticles as drug delivery systems. Pharmaceutics. 2020;12(7):604. doi:10.3390/pharmaceutics12070604", "ArticleIdList": ["10.3390/pharmaceutics12070604", "PMC7407889", "32610448"]}, {"Citation": "Jain A, Singh SK, Arya SK, Kundu SC, Kapoor S. Protein nanoparticles: promising platforms for drug delivery. ACS Biomater Sci Eng. 2018;4(12):3939\u20133961. doi:10.1021/acsbiomaterials.8b01098", "ArticleIdList": ["10.1021/acsbiomaterials.8b01098", "33418796"]}, {"Citation": "Takakura Y, Fujita T, Hashida M, Sezaki H. Disposition characteristics of macromolecules in tumor-bearing mice. Pharm Res. 1990;7(4):339\u2013346. doi:10.1023/a:1015807119753", "ArticleIdList": ["10.1023/a:1015807119753", "1694582"]}, {"Citation": "Miele E, Spinelli GP, Miele E, Tomao F, Tomao S. Albumin-bound formulation of paclitaxel (Abraxane\u00ae ABI-007) in the treatment of breast cancer. Int J Nanomedicine. 2009;4:99. doi:10.2147/ijn.s3061", "ArticleIdList": ["10.2147/ijn.s3061", "PMC2720743", "19516888"]}, {"Citation": "Wolfram J, Ferrari M. Clinical cancer nanomedicine. Nano Today. 2019;25:85\u201398. doi:10.1016/j.nantod.2019.02.005", "ArticleIdList": ["10.1016/j.nantod.2019.02.005", "PMC6662733", "31360214"]}, {"Citation": "Gonzalez-Angulo AM, Meric-Bernstam F, Chawla S, et al. Weekly nab-rapamycin in patients with advanced nonhematologic malignancies: final results of a phase 1 trial. Clin Cancer Res. 2013;19(19):5474\u20135484. doi:10.1158/1078-0432.CCR-12-3110", "ArticleIdList": ["10.1158/1078-0432.CCR-12-3110", "PMC3935482", "24089446"]}, {"Citation": "Kesari S, Juarez T, Carrillo J, et al. RBTT-01. A phase 2 trial with ABI-009 (nab-sirolimus) as single-agent and combinations in recurrent high-grade glioma (rHGG) and in newly diagnosed glioblastoma (ndGBM). Neuro Oncol. 2019;21(Suppl6):vi218\u2013vi219. doi:10.1093/neuonc/noz175.913", "ArticleIdList": ["10.1093/neuonc/noz175.913"]}, {"Citation": "Wagner AJ, Ravi V, Ganjoo KN, et al. ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): preliminary efficacy, safety, and mutational status from AMPECT, an open label phase II registration trial. J Clin Oncol. 2019;37(15):11005. doi:10.1200/JCO.2019.37.15_suppl.11005", "ArticleIdList": ["10.1200/JCO.2019.37.15_suppl.11005"]}, {"Citation": "Desai N, Momin M, Khan T, Gharat S, Ningthoujam RS, Omri A. Metallic nanoparticles as drug delivery system for the treatment of cancer. Expert Opin Drug Deliv. 2021;1\u201330. doi:10.1080/17425247.2021.1912008", "ArticleIdList": ["10.1080/17425247.2021.1912008", "33793359"]}, {"Citation": "Sharma A, Goyal AK, Rath G. Recent advances in metal nanoparticles in cancer therapy. J Drug Target. 2018;26(8):617\u2013632. doi:10.1080/1061186X.2017.1400553", "ArticleIdList": ["10.1080/1061186X.2017.1400553", "29095640"]}, {"Citation": "Chugh H, Sood D, Chandra I, Tomar V, Dhawan G, Chandra R. Role of gold and silver nanoparticles in cancer nano-medicine. Artif Cells Nanomedicine Biotechnol. 2018;46:1210\u20131220. doi:10.1080/21691401.2018.1449118", "ArticleIdList": ["10.1080/21691401.2018.1449118", "29533101"]}, {"Citation": "Vinardell MP, Mitjans M. Antitumor activities of metal oxide nanoparticles. Nanomaterials. 2015;5(2):1004\u20131021. doi:10.3390/nano5021004", "ArticleIdList": ["10.3390/nano5021004", "PMC5312892", "28347048"]}, {"Citation": "Cherukuri P, Glazer ES, Curley SA. Targeted hyperthermia using metal nanoparticles. Adv Drug Deliv Rev. 2010;62(3):339\u2013345. doi:10.1016/j.addr.2009.11.006", "ArticleIdList": ["10.1016/j.addr.2009.11.006", "PMC2827640", "19909777"]}, {"Citation": "Gobbo OL, Sjaastad K, Radomski MW, Volkov Y, Prina-Mello A. Magnetic nanoparticles in cancer theranostics. Theranostics. 2015;5(11):1249\u20131263. doi:10.7150/thno.11544", "ArticleIdList": ["10.7150/thno.11544", "PMC4568452", "26379790"]}, {"Citation": "Ahmad MZ, Akhter S, Jain GK, et al. Metallic nanoparticles: technology overview & drug delivery applications in oncology. Expert Opin Drug Deliv. 2010;7(8):927\u2013942. doi:10.1517/17425247.2010.498473", "ArticleIdList": ["10.1517/17425247.2010.498473", "20645671"]}, {"Citation": "Anderson SD, Gwenin VV, Gwenin CD. Magnetic functionalized nanoparticles for biomedical, drug delivery and imaging applications. Nanoscale Res Lett. 2019;14:1\u201316. doi:10.1186/s11671-019-3019-6", "ArticleIdList": ["10.1186/s11671-019-3019-6", "PMC6542970", "31147786"]}, {"Citation": "Anselmo AC, Mitragotri S. A review of clinical translation of inorganic nanoparticles. AAPS J. 2015;17(5):1041\u20131054. doi:10.1208/s12248-015-9780-2", "ArticleIdList": ["10.1208/s12248-015-9780-2", "PMC4540735", "25956384"]}, {"Citation": "Libutti SK, Paciotti GF, Byrnes AA, et al. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res. 2010;16(24):6139\u20136149. doi:10.1158/1078-0432.CCR-10-0978", "ArticleIdList": ["10.1158/1078-0432.CCR-10-0978", "PMC3004980", "20876255"]}, {"Citation": "Schrand AM, Rahman MF, Hussain SM, Schlager JJ, Smith DA, Syed AF. Metal-based nanoparticles and their toxicity assessment. Nanomed Nanobiotechnol. 2010;2(5):544\u2013568. doi:10.1002/wnan.103", "ArticleIdList": ["10.1002/wnan.103", "20681021"]}, {"Citation": "Mohamed Isa ED, Ahmad H, Abdul Rahman MB, Gill MR. Progress in mesoporous silica nanoparticles as drug delivery agents for cancer treatment. Pharmaceutics. 2021;13(2):152. doi:10.3390/pharmaceutics13020152", "ArticleIdList": ["10.3390/pharmaceutics13020152", "PMC7911720", "33498885"]}, {"Citation": "Vallet-Reg\u00ed M, Colilla M, Izquierdo-Barba I, Manzano M. Mesoporous silica nanoparticles for drug delivery: current insights. Molecules. 2018;23(1):47. doi:10.3390/molecules23010047", "ArticleIdList": ["10.3390/molecules23010047", "PMC5943960", "29295564"]}, {"Citation": "Lodha A, Lodha M, Patel A, et al. Synthesis of mesoporous silica nanoparticles and drug loading of poorly water soluble drug cyclosporin A. J Pharm Bioallied Sci. 2012;4:S92\u2013S94. doi:10.4103/0975-7406.94153", "ArticleIdList": ["10.4103/0975-7406.94153", "PMC3467849", "23066223"]}, {"Citation": "Li T, Shi S, Goel S, et al. Recent advancements in mesoporous silica nanoparticles towards therapeutic applications for cancer. Acta Biomater. 2019;89:1\u201313. doi:10.1016/j.actbio.2019.02.031", "ArticleIdList": ["10.1016/j.actbio.2019.02.031", "30797106"]}, {"Citation": "Vallet-Reg\u00ed M, R\u00e1mila A, Del Real RP, P\u00e9rez-Pariente J. A new property of MCM-41: drug delivery system. Chem Mater. 2001;13:308\u2013311. doi:10.1021/cm0011559", "ArticleIdList": ["10.1021/cm0011559"]}, {"Citation": "Bhavsar DB, Patel V, Sawant KK. Design and characterization of dual responsive mesoporous silica nanoparticles for breast cancer targeted therapy. Eur J Pharm Sci. 2020;152:105428. doi:10.1016/j.ejps.2020.105428", "ArticleIdList": ["10.1016/j.ejps.2020.105428", "32553643"]}, {"Citation": "Hanafi-Bojd MY, Moosavian Kalat SA, Taghdisi SM, Ansari L, Abnous K, Malaekeh-Nikouei B. MUC1 aptamer-conjugated mesoporous silica nanoparticles effectively target breast cancer cells. Drug Dev Ind Pharm. 2018;44(1):13\u201318. doi:10.1080/03639045.2017.1371734", "ArticleIdList": ["10.1080/03639045.2017.1371734", "28832225"]}, {"Citation": "Wang Y, Xie Y, Kilchrist KV, Li J, Duvall CL, Oupick\u00fd D. Endosomolytic and tumor-penetrating mesoporous silica nanoparticles for siRNA/miRNA combination cancer therapy. ACS Appl Mater Interfaces. 2020;12(4):4308\u20134322. doi:10.1021/acsami.9b21214", "ArticleIdList": ["10.1021/acsami.9b21214", "PMC7011569", "31939276"]}, {"Citation": "Ngamcherdtrakul W, Morry J, Gu S, et al. Cationic polymer modified mesoporous silica nanoparticles for targeted siRNA delivery to HER2+ breast cancer. Adv Funct Mater. 2015;25(18):2646\u20132659. doi:10.1002/adfm.201404629", "ArticleIdList": ["10.1002/adfm.201404629", "PMC4469082", "26097445"]}, {"Citation": "Hozayen WG, Mahmoud AM, Desouky EM, El-Nahass ES, Soliman HA, Farghali AA. Cardiac and pulmonary toxicity of mesoporous silica nanoparticles is associated with excessive ROS production and redox imbalance in Wistar rats. Biomed Pharmacother. 2019;109:2527\u20132538. doi:10.1016/j.biopha.2018.11.093", "ArticleIdList": ["10.1016/j.biopha.2018.11.093", "30551513"]}, {"Citation": "Li L, Liu T, Fu C, Tan L, Meng X, Liu H. Biodistribution, excretion, and toxicity of mesoporous silica nanoparticles after oral administration depend on their shape. Nanomedicine. 2015;11(8):1915\u20131924. doi:10.1016/j.nano.2015.07.004", "ArticleIdList": ["10.1016/j.nano.2015.07.004", "26238077"]}, {"Citation": "Zhang Q, Xu H, Zheng S, Su M, Wang J. Genotoxicity of mesoporous silica nanoparticles in human embryonic kidney 293 cells. Drug Test Anal. 2015;7(9):787\u2013796. doi:10.1002/dta.1773", "ArticleIdList": ["10.1002/dta.1773", "25583601"]}, {"Citation": "Herranz-L\u00f3pez M, Losada-Echeberr\u00eda M, Barraj\u00f3n-Catal\u00e1n E. The multitarget activity of natural extracts on cancer: synergy and xenohormesis. Medicines. 2019;6(1):6. doi:10.3390/medicines6010006", "ArticleIdList": ["10.3390/medicines6010006", "PMC6473537", "30597909"]}, {"Citation": "Dehdari S, Hajimehdipoor H. Medicinal properties of Adiantum capillus-veneris Linn. in traditional medicine and modern phytotherapy: a review article. Iran J Public Health. 2018;47(2):188\u2013197.", "ArticleIdList": ["PMC5810381", "29445628"]}, {"Citation": "Ibraheim ZZ, Ahmed AS, Gouda YG. Phytochemical and biological studies of Adiantum capillus-veneris L. Saudi Pharm J. 2011;19(2):65\u201374. doi:10.1016/j.jsps.2011.01.007", "ArticleIdList": ["10.1016/j.jsps.2011.01.007", "PMC3745073", "23960744"]}, {"Citation": "Ranjan V, Vats M, Gupta N, Sardana S. Antidiabetic potential of whole plant of Adiantum capillus veneris linn. in streptozotocin induced diabetic rats. Int J Pharm Clin Res. 2014;6(4):341\u2013347."}, {"Citation": "Khoramian L, Sajjadi SE, Minaiyan M. Anti-inflammatory effect of Adiantum capillus-veneris hydroalcoholic and aqueous extracts on acetic acid-induced colitis in rats. Avicenna J Phytomed. 2020;10(5):492\u2013503.", "ArticleIdList": ["PMC7508316", "32995327"]}, {"Citation": "Singh M, Singh N, Khare PB, Rawat AK. Antimicrobial activity of some important Adiantum species used traditionally in indigenous systems of medicine. J Ethnopharmacol. 2008;115(2):327\u2013329. doi:10.1016/j.jep.2007.09.018", "ArticleIdList": ["10.1016/j.jep.2007.09.018", "17997240"]}, {"Citation": "Haider S, Nazreen S, Alam MM, Gupta A, Hamid H, Alam MS. Anti-inflammatory and anti-nociceptive activities of ethanolic extract and its various fractions from Adiantum capillus veneris Linn. J Ethnopharmacol. 2011;138(3):741\u2013747. doi:10.1016/j.jep.2011.10.012", "ArticleIdList": ["10.1016/j.jep.2011.10.012", "22020277"]}, {"Citation": "Al-Hallaq EK, Litescu SC, Kasabri V, Abdul-Razzak KK, Afifi F. Hypocholesterolemic effects of Adiantum capillus veneris L. aqueous extract in high cholesterol diet-fed rats and HPLC-MS determination of its polyphenolics. Rev Roum Chim. 2015;6(2\u20133):355\u2013363."}, {"Citation": "Nilforoushzadeh MA, Javanmard SH, Ghanadian M, et al. The effects of Adiantum capillus-veneris on wound healing: an experimental in vitro evaluation. Int J Prev Med. 2014;5(10):1261\u20131268.", "ArticleIdList": ["PMC4223945", "25400884"]}, {"Citation": "Roy SC, Sajeeb BK, Muhit MA, Bachar SC. Evaluation of antioxidant and cytotoxic activities of aerial parts of Adiantum capillus-veneris L. growing in Bangladesh. Dhaka Univ J Pharm Sci. 2019;18(2):217\u2013222. doi:10.3329/dujps.v18i2.43264", "ArticleIdList": ["10.3329/dujps.v18i2.43264"]}, {"Citation": "Zhang L, Zhang LB. Phylogeny and systematics of the brake fern genus Pteris (Pteridaceae) based on molecular (plastid and nuclear) and morphological evidence. Mol Phylogenet Evol. 2018;118:265\u2013285. doi:10.1016/j.ympev.2017.09.011", "ArticleIdList": ["10.1016/j.ympev.2017.09.011", "28951191"]}, {"Citation": "Cao H, Chai TT, Wang X, et al. Phytochemicals from fern species: potential for medicine applications. Phytochem Rev. 2017;16(3):379\u2013440. doi:10.1007/s11101-016-9488-7", "ArticleIdList": ["10.1007/s11101-016-9488-7", "PMC7089528", "32214919"]}, {"Citation": "Rautray S, Panikar S, Amutha T, Rajananthini AU. Anticancer activity of Adiantum capillus veneris and Pteris quadriureta L. in human breast cancer cell lines. Mol Biol Rep. 2018;45(6):1897\u20131911. doi:10.1007/s11033-018-4337-y", "ArticleIdList": ["10.1007/s11033-018-4337-y", "30194562"]}, {"Citation": "Rautray S, Panikar S, Sofia A, Rajananthini AU. Anti-oxidant and anti-microbial study of Adiantum capillus veneris and Pteris quadriureta L. J Med Plants Res. 2018;12(23):359\u2013368. doi:10.5897/JMPR2018.6635", "ArticleIdList": ["10.5897/JMPR2018.6635"]}, {"Citation": "Gavamukulya Y, Wamunyokoli F, El-Shemy HA. Annona muricata: is the natural therapy to most disease conditions including cancer growing in our backyard? A systematic review of its research history and future prospects. Asian Pac J Trop Med. 2017;10(9):835\u2013848. doi:10.1016/j.apjtm.2017.08.009", "ArticleIdList": ["10.1016/j.apjtm.2017.08.009", "29080611"]}, {"Citation": "Moghadamtousi SZ, Fadaeinasab M, Nikzad S, Mohan G, Ali HM, Kadir HA. Annona muricata (Annonaceae): a review of its traditional uses, isolated acetogenins and biological activities. Int J Mol Sci. 2015;16(7):15625\u201315658. doi:10.3390/ijms160715625", "ArticleIdList": ["10.3390/ijms160715625", "PMC4519917", "26184167"]}, {"Citation": "Chan P, Ah R, Mh K. Anti-arthritic activities of Annona muricata L. Leaves extract on complete freund\u2019s adjuvant (CFA)-induced arthritis in rats. Planta Med. 2010;76:P166. doi:10.1055/s-0030-1264464", "ArticleIdList": ["10.1055/s-0030-1264464"]}, {"Citation": "N\u2019Gouemo P, Koudogbo B, Tchivounda HP, Akono\u2010Nguema C, Etoua MM. Effects of ethanol extract of Annona muricata on pentylenetetrazol\u2010induced convulsive seizures in mice. Phyther Res. 1997;11(3):243\u2013245. doi:10.1002/(SICI)1099-1573(199705)11:3<243::AID-PTR66>3.0.CO;2-A", "ArticleIdList": ["10.1002/(SICI)1099-1573(199705)11:3<243::AID-PTR66>3.0.CO;2-A"]}, {"Citation": "Adeyemi DO, Komolafe OA, Adewole OS, Obuotor EM, Adenowo TK. Anti hyperglycemic activities of Annona muricata (Linn). African J Tradit Complement Altern Med. 2008;6(1):62\u201369.", "ArticleIdList": ["PMC2816521", "20162043"]}, {"Citation": "Ola-Davies OE, Oyagbemi AA, Omobowale TO, Akande I, Ashafa A. Ameliorative effects of Annona muricata Linn. (Annonaceae) against potassium dichromate-induced hypertension in vivo: involvement of Kim-1/p38 MAPK/Nrf2 signaling. J Basic Clin Physiol Pharmacol. 2019;30(4):1\u201321. doi:10.1515/jbcpp-2018-0172", "ArticleIdList": ["10.1515/jbcpp-2018-0172", "31050655"]}, {"Citation": "George VC, Kumar DR, Suresh PK, Kumar RA. Antioxidant, DNA protective efficacy and HPLC analysis of Annona muricata (soursop) extracts. J Food Sci Technol. 2015;52(4):2328\u20132335. doi:10.1007/s13197-014-1289-7", "ArticleIdList": ["10.1007/s13197-014-1289-7", "PMC4375238", "25829616"]}, {"Citation": "Miranda NC, Araujo ECB, Justino AB, et al. Anti-parasitic activity of Annona muricata L. leaf ethanolic extract and its fractions against Toxoplasma gondii in vitro and in vivo. J Ethnopharmacol. 2021;273:114019. doi:10.1016/j.jep.2021.114019", "ArticleIdList": ["10.1016/j.jep.2021.114019", "33716084"]}, {"Citation": "de La Cruz AMA, Catabay AP. Hypolipidemic effect of the lyophilized fruit pulp of guyabano, Annona muricata Linn. (Fam. Annonaceae) in atherogenic diet-induced hyperlipidemia in albino rats. J Asian Assoc Sch Pharm. 2016;5:351\u2013359."}, {"Citation": "Moghadamtousi SZ, Rouhollahi E, Hajrezaie M, Karimian H, Abdulla MA, Kadir HA. Annona muricata leaves accelerate wound healing in rats via involvement of Hsp70 and antioxidant defence. Int J Surg. 2015;18:110\u2013117. doi:10.1016/j.ijsu.2015.03.026", "ArticleIdList": ["10.1016/j.ijsu.2015.03.026", "25899210"]}, {"Citation": "Moghadamtousi SZ, Rouhollahi E, Karimian H, Fadaeinasab M, Abdulla MA, Kadir HA. Gastroprotective activity of Annona muricata leaves against ethanol-induced gastric injury in rats via Hsp70/Bax involvement. Drug Des Devel Ther. 2014;8:2099\u20132110. doi:10.2147/DDDT.S70096", "ArticleIdList": ["10.2147/DDDT.S70096", "PMC4218895", "25378912"]}, {"Citation": "Padma P, Chansouria JP, Khosa RL. Hepatoprotective activity of Annona muricata Linn. and Polyalthia cerasoides bedd. Anc Sci Life. 1999;19(1\u20132):7\u201310.", "ArticleIdList": ["PMC3336466", "22556909"]}, {"Citation": "Ishola IO, Awodele O, Olusayero AM, Ochieng CO. Mechanisms of analgesic and anti-inflammatory properties of Annona muricata Linn. (Annonaceae) fruit extract in rodents. J Med Food. 2014;17(12):1375\u20131382. doi:10.1089/jmf.2013.0088", "ArticleIdList": ["10.1089/jmf.2013.0088", "PMC4259190", "25133801"]}, {"Citation": "Syed Najmuddin SUF, Romli MF, Hamid M, Alitheen NB, Nik Abd Rahman NMA. Anti-cancer effect of Annona Muricata Linn leaves crude extract (AMCE) on breast cancer cell line. BMC Complement Altern Med. 2016;16(1):311. doi:10.1186/s12906-016-1290-y", "ArticleIdList": ["10.1186/s12906-016-1290-y", "PMC4997662", "27558166"]}, {"Citation": "Prasad SK, Veeresh PM, Ramesh PS, Natraj SM, Madhunapantula SV, Devegowda D. Phytochemical fractions from Annona muricata seeds and fruit pulp inhibited the growth of breast cancer cells through cell cycle arrest at G 0/G 1 phase. J Cancer Res Ther. 2020;16(6):1235\u20131249. doi:10.4103/jcrt.JCRT_494_19", "ArticleIdList": ["10.4103/jcrt.JCRT_494_19", "33342779"]}, {"Citation": "Alshaeri HK, Alasmari MM, Natto ZS, Pino-Figueroa A. Effects of Annona muricata extract on triple-negative breast cancer cells mediated through EGFR signaling. Cancer Manag Res. 2020;12:12519\u201312526. doi:10.2147/CMAR.S278647", "ArticleIdList": ["10.2147/CMAR.S278647", "PMC7723033", "33304106"]}, {"Citation": "Naik AV, Sellappan K. In vitro evaluation of Annona muricata L. (Soursop) leaf methanol extracts on inhibition of tumorigenicity and metastasis of breast cancer cells. Biomarkers. 2020;25(8):701\u2013710. doi:10.1080/1354750X.2020.1836025", "ArticleIdList": ["10.1080/1354750X.2020.1836025", "33048613"]}, {"Citation": "Sabapati M, Palei NN, Ashok Kumar CK, Molakpogu RB. Solid lipid nanoparticles of Annona muricata fruit extract: formulation, optimization and in vitro cytotoxicity studies. Drug Dev Ind Pharm. 2019;45(4):577\u2013586. doi:10.1080/03639045.2019.1569027", "ArticleIdList": ["10.1080/03639045.2019.1569027", "30663427"]}, {"Citation": "Jabir MS, Saleh YM, Sulaiman GM, et al. Green synthesis of silver nanoparticles using Annona muricata extract as an inducer of apoptosis in cancer cells and inhibitor for NLRP3 inflammasome via enhanced autophagy. Nanomaterials. 2021;11(2):384. doi:10.3390/nano11020384", "ArticleIdList": ["10.3390/nano11020384", "PMC7913157", "33546151"]}, {"Citation": "Gupta S, Ved A. Operculina turpethum (Linn.) Silva Manso as a medicinal plant species: a review on bioactive components and pharmacological properties. Pharmacogn Rev. 2017;11(22):158\u2013166. doi:10.4103/phrev.phrev_6_17", "ArticleIdList": ["10.4103/phrev.phrev_6_17", "PMC5628523", "28989252"]}, {"Citation": "Ignatius V, Narayanan M, Subramanian V, Periyasamy BM. Antiulcer activity of indigenous plant Operculina turpethum Linn. Evid-Based Complement Altern Med. 2013;2013:272134. doi:10.1155/2013/272134", "ArticleIdList": ["10.1155/2013/272134", "PMC3582069", "23476683"]}, {"Citation": "Anbuselvam C, Vijayavel K, Balasubramanian MP. Protective effect of Operculina turpethum against 7,12-dimethyl benz(a)anthracene induced oxidative stress with reference to breast cancer in experimental rats. Chem Biol Interact. 2007;168(3):229\u2013236. doi:10.1016/j.cbi.2007.04.007", "ArticleIdList": ["10.1016/j.cbi.2007.04.007", "17531963"]}, {"Citation": "Mughees M, Wajid S. Evaluation of cytotoxicity of different part extracts of Ipomoea turpethum against breast cancer cell lines. J Environ Pathol Toxicol Oncol. 2020;39(1):51\u201360. doi:10.1615/JEnvironPatholToxicolOncol.2020031451", "ArticleIdList": ["10.1615/JEnvironPatholToxicolOncol.2020031451", "32479012"]}, {"Citation": "Mughees M, Samim M, Sharma Y, Wajid S. Identification of protein targets and the mechanism of the cytotoxic action of Ipomoea turpethum extract loaded nanoparticles against breast cancer cells. J Mater Chem B. 2019;7(39):6048\u20136063. doi:10.1039/c9tb00824a", "ArticleIdList": ["10.1039/c9tb00824a", "31549130"]}, {"Citation": "Zhang W, Yu L, Ji T, Wang C. Tumor microenvironment\u2013responsive peptide-based supramolecular drug delivery system. Front Chem. 2020;8:549. doi:10.3389/fchem.2020.00549", "ArticleIdList": ["10.3389/fchem.2020.00549", "PMC7388741", "32775317"]}, {"Citation": "Polito L, Bortolotti M, Maiello S, Battelli MG, Bolognesi A. Plants producing ribosome-inactivating proteins in traditional medicine. Molecules. 2016;21(11):1560. doi:10.3390/molecules21111560", "ArticleIdList": ["10.3390/molecules21111560", "PMC6273415", "27869738"]}, {"Citation": "Stirpe F. Ribosome-inactivating proteins: from toxins to useful proteins. Toxicon. 2013;67:12\u201316. doi:10.1016/j.toxicon.2013.02.005", "ArticleIdList": ["10.1016/j.toxicon.2013.02.005", "23462379"]}, {"Citation": "Zhu F, Zhou YK, Ji ZL, Chen X. The plant ribosome-inactivating proteins play important roles in defense against pathogens and insect pest attacks. Front Plant Sci. 2018;9:146. doi:10.3389/fpls.2018.00146", "ArticleIdList": ["10.3389/fpls.2018.00146", "PMC5811460", "29479367"]}, {"Citation": "Sismindari SU, Mae Sri Hartati W, Adhyatmika A, Retno Sunarminingsih S. Cytotoxic selectivity of MJC0.3 and MJC0.5, acidic ribosome-inactivating proteins isolated from Mirabilis jalapa L. leaves against various cancer cell-lines. J Med Sci. 2010;42(1):39\u201343."}, {"Citation": "Wicaksono PA, Name S, Martien R, Ismail H. Formulation and cytotoxicity of ribosome-inactivating protein Mirabilis Jalapa L. nanoparticles using alginate-low viscosity chitosan conjugated with anti-Epcam antibodies in the T47D breast cancer cell line. Asian Pacific J Cancer Prev. 2016;17(4):2277\u20132284. doi:10.7314/apjcp.2016.17.4.2277", "ArticleIdList": ["10.7314/apjcp.2016.17.4.2277", "27221930"]}, {"Citation": "Cimino A, Halushka M, Illei P, Wu X, Sukumar S, Argani P. Epithelial cell adhesion molecule (EpCAM) is overexpressed in breast cancer metastases. Breast Cancer Res Treat. 2010;123(3):701\u2013708. doi:10.1007/s10549-009-0671-z", "ArticleIdList": ["10.1007/s10549-009-0671-z", "PMC3042397", "20012351"]}, {"Citation": "Brandao EM, Brand\u00e3o PH, Souza IA, Paiva GS, de C Carvalho M, Lacerda CM. Antineoplasic effect of aqueous extract of Plectranthus amboinicus in Ehrlich ascites carcinoma. J Cancer. 2013;4(7):573\u2013576. doi:10.7150/jca.6730", "ArticleIdList": ["10.7150/jca.6730", "PMC3753532", "23983822"]}, {"Citation": "Gurgel AP, da Silva JG, Grangeiro AR, et al. In vivo study of the anti-inflammatory and antitumor activities of leaves from Plectranthus amboinicus (Lour.) Spreng (Lamiaceae). J Ethnopharmacol. 2009;125(2):361\u2013363. doi:10.1016/j.jep.2009.07.006", "ArticleIdList": ["10.1016/j.jep.2009.07.006", "19607901"]}, {"Citation": "Almalki A, Abutaha N, Al-Doaiss AA, Mohammed AZ, Wadaan MA. Cytotoxicity, in vivo toxicity, and chemical composition of the hexane extract of Plectranthus amboinicus (Lour.) Spreng. Environ Sci Pollut Res. 2021;28(35):48141\u201348153. doi:10.1007/s11356-021-13796-8", "ArticleIdList": ["10.1007/s11356-021-13796-8", "33899147"]}, {"Citation": "Hasibuan PAZ, Sitorus P, Satria D, Sibuea RD. Antioxidant properties and cytotoxic activity of ethyl acetate fraction of Plectranthus amboinicus (Lour.) Spreng. leaves on HeLa and T47D cell lines. Indones J Cancer Chemoprevention. 2019;10(1):37\u201345. doi:10.14499/indonesianjcanchemoprev10iss1pp37-45", "ArticleIdList": ["10.14499/indonesianjcanchemoprev10iss1pp37-45"]}, {"Citation": "Rai V, Pai VR, Kedilaya P. A preliminary evaluation of anticancer and antioxidant potential of two traditional medicinal plants from Lamiaceae-Pogostemon heyneanus and Plectranthus amboinicus. J Appl Pharm Sci. 2016;6(8):73\u201378. doi:10.7324/JAPS.2016.60811", "ArticleIdList": ["10.7324/JAPS.2016.60811"]}, {"Citation": "Yulianto W, Andarwulan N, Giriwono PE, Pamungkas J. HPLC-based metabolomics to identify cytotoxic compounds from Plectranthus amboinicus (Lour.) Spreng against human breast cancer MCF-7Cells. J Chromatogr B Anal Technol Biomed Life Sci. 2016;1039:28\u201334. doi:10.1016/j.jchromb.2016.10.024", "ArticleIdList": ["10.1016/j.jchromb.2016.10.024", "27816313"]}, {"Citation": "Hasibuan PAZ, Sumaiyah S. The anti-proliferative and pro-apoptotic properties of ethanol Plectranthus amboinicus (Lour.) Spreng. leaves ethanolic extract nanoparticles on T47D cell lines. Asian Pacific J Cancer Prev. 2019;20(3):897\u2013901. doi:10.31557/APJCP.2019.20.3.897", "ArticleIdList": ["10.31557/APJCP.2019.20.3.897", "PMC6825766", "30912412"]}, {"Citation": "Bassiri-Jahromi S. Punica granatum (Pomegranate) activity in health promotion and cancer prevention. Oncol Rev. 2018;12(1):345. doi:10.4081/oncol.2018.345", "ArticleIdList": ["10.4081/oncol.2018.345", "PMC5806496", "29441150"]}, {"Citation": "Zarfeshany A, Asgary S, Javanmard SH. Potent health effects of pomegranate. Adv Biomed Res. 2014;3:100. doi:10.4103/2277-9175.129371", "ArticleIdList": ["10.4103/2277-9175.129371", "PMC4007340", "24800189"]}, {"Citation": "Ge S, Duo L, Wang J, et al. A unique understanding of traditional medicine of pomegranate, Punica granatum L. and its current research status. J Ethnopharmacol. 2021;271:113877. doi:10.1016/j.jep.2021.113877", "ArticleIdList": ["10.1016/j.jep.2021.113877", "33515685"]}, {"Citation": "Al-Zoreky NS. Antimicrobial activity of pomegranate (Punica granatum L.) fruit peels. Int J Food Microbiol. 2009;134(3):244\u2013248. doi:10.1016/j.ijfoodmicro.2009.07.002", "ArticleIdList": ["10.1016/j.ijfoodmicro.2009.07.002", "19632734"]}, {"Citation": "Gil MI, Tom\u00e1s-Barber\u00e1n FA, Hess-Pierce B, Holcroft DM, Kader AA. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J Agric Food Chem. 2000;48(10):4581\u20134589. doi:10.1021/jf000404a", "ArticleIdList": ["10.1021/jf000404a", "11052704"]}, {"Citation": "Lukiswanto BS, Miranti A, Sudjarwo SA, Primarizky H, Yuniarti WM. Evaluation of wound healing potential of pomegranate (Punica granatum) whole fruit extract on skin burn wound in rats (Rattus norvegicus). J Adv Vet Anim Res. 2019;6(2):202\u2013207. doi:10.5455/javar.2019.f333", "ArticleIdList": ["10.5455/javar.2019.f333", "PMC6702873", "31453192"]}, {"Citation": "Razani Z, Dastani M, Kazerani HR. Cardioprotective effects of pomegranate (Punica granatum) juice in patients with ischemic heart disease. Phyther Res. 2017;31(11):1731\u20131738. doi:10.1002/ptr.5901", "ArticleIdList": ["10.1002/ptr.5901", "28913846"]}, {"Citation": "Gonz\u00e1lez-Trujano ME, Pellicer F, Mena P, Moreno DA, Garc\u00eda-Viguera C. Antinociceptive and anti-inflammatory activities of a pomegranate (Punica granatum L.) extract rich in ellagitannins. Int J Food Sci Nutr. 2015;66(4):395\u2013399. doi:10.3109/09637486.2015.1024208", "ArticleIdList": ["10.3109/09637486.2015.1024208", "25822007"]}, {"Citation": "Khan GN, Gorin MA, Rosenthal D, et al. Pomegranate fruit extract impairs invasion and motility in human breast cancer. Integr Cancer Ther. 2009;8(3):242\u2013253. doi:10.1177/1534735409341405", "ArticleIdList": ["10.1177/1534735409341405", "19815594"]}, {"Citation": "Ahmadiankia N, Bagheri M, Fazli M. Gene expression changes in pomegranate peel extract-treated triple-negative breast cancer cells. Reports Biochem Mol Biol. 2018;7(1):102\u2013109.", "ArticleIdList": ["PMC6175583", "30324124"]}, {"Citation": "Bagheri M, Fazli M, Saeednia S, Kor A, Ahmadiankia N. Pomegranate peel extract inhibits expression of \u03b2-catenin, epithelial mesenchymal transition, and metastasis in triple negative breast cancer cells. Cell Mol Biol. 2018;64(7):86\u201391. doi:10.14715/cmb/2018.64.7.15", "ArticleIdList": ["10.14715/cmb/2018.64.7.15", "29974851"]}, {"Citation": "Shirode AB, Kovvuru P, Chittur SV, Henning SM, Heber D, Reliene R. Antiproliferative effects of pomegranate extract in MCF-7 breast cancer cells are associated with reduced DNA repair gene expression and induction of double strand breaks. Mol Carcinog. 2014;53(6):458\u2013470. doi:10.1002/mc.21995", "ArticleIdList": ["10.1002/mc.21995", "23359482"]}, {"Citation": "Sreeja S, Santhosh Kumar TR, Lakshmi BS, Sreeja S. Pomegranate extract demonstrate a selective estrogen receptor modulator profile in human tumor cell lines and in vivo models of estrogen deprivation. J Nutr Biochem. 2012;23(7):725\u2013732. doi:10.1016/j.jnutbio.2011.03.015", "ArticleIdList": ["10.1016/j.jnutbio.2011.03.015", "21839626"]}, {"Citation": "Shirode AB, Bharali DJ, Nallanthighal S, Coon JK, Mousa SA, Reliene R. Nanoencapsulation of pomegranate bioactive compounds for breast cancer chemoprevention. Int J Nanomedicine. 2015;10:475\u2013484. doi:10.2147/IJN.S65145", "ArticleIdList": ["10.2147/IJN.S65145", "PMC4296962", "25624761"]}, {"Citation": "Badawi NM, Teaima MH, El-Say KM, Attia DA, El-Nabarawi MA, Elmazar MM. Pomegranate extract-loaded solid lipid nanoparticles: design, optimization, and in vitro cytotoxicity study. Int J Nanomedicine. 2018;13:1313\u20131326. doi:10.2147/IJN.S154033", "ArticleIdList": ["10.2147/IJN.S154033", "PMC5846752", "29563789"]}, {"Citation": "Wansi JD, Wandji J, Sewald N, Nahar L, Martin C, Sarker SD. Phytochemistry and pharmacology of the genus Drypetes: a review. J Ethnopharmacol. 2016;190:328\u2013353. doi:10.1016/j.jep.2016.06.060", "ArticleIdList": ["10.1016/j.jep.2016.06.060", "27353868"]}, {"Citation": "Mishra S, Kumar S, Darokar MP, Shanker K. Novel bioactive compound from the bark of Putranjiva roxburghii Wall. Nat Prod Res. 2019;35(4):1\u20133. doi:10.1080/14786419.2019.1633650", "ArticleIdList": ["10.1080/14786419.2019.1633650", "31232117"]}, {"Citation": "Kala C, Imam SS, Taleuzzaman M, et al. Extraction, GC-MS evaluation and anti-epileptic potential of seeds ethanolic extract of Putranjiva roxburghii Wall. Cent Nerv Syst Agents Med Chem. 2020;20(3):186\u2013193. doi:10.2174/1871524920999201027125743", "ArticleIdList": ["10.2174/1871524920999201027125743", "33109052"]}, {"Citation": "Reanmongkol W, Noppapan T, Subhadhirasakul S. Antinociceptive, antipyretic, and anti-inflammatory activities of Putranjiva roxburghii Wall. leaf extract in experimental animals. J Nat Med. 2009;63(3):290\u2013296. doi:10.1007/s11418-009-0336-6", "ArticleIdList": ["10.1007/s11418-009-0336-6", "19387768"]}, {"Citation": "Shivalingegowda M, Ekambaram H, Manjunath K. Antimicrobial, antioxidant and cytotoxic activity of methanolic leaf extract of Putranjiva roxburghii: an in-vitro study. Solid State Technol. 2020;63(6):13199\u201313210."}, {"Citation": "Balkrishna A, Sharma VK, Das SK, et al. Characterization and anti-cancerous effect of Putranjiva roxburghii seed extract mediated silver nanoparticles on human colon (HCT-116), pancreatic (PANC-1) and breast (MDA-MB 231) cancer cell lines: a comparative study. Int J Nanomedicine. 2020;15:573\u2013585. doi:10.2147/IJN.S230244", "ArticleIdList": ["10.2147/IJN.S230244", "PMC6986406", "32158209"]}, {"Citation": "Nayaka S, Bhat MP, Chakraborty B, et al. Seed extract-mediated synthesis of silver nanoparticles from Putranjiva roxburghii Wall.: phytochemical characterization, antibacterial activity and anticancer activity against MCF-7 cell line. Indian J Pharm Sci. 2020;82(2):260\u2013269. doi:10.36468/pharmaceutical-sciences.646", "ArticleIdList": ["10.36468/pharmaceutical-sciences.646"]}, {"Citation": "Salehi F, Behboudi H, Kavoosi G, Ardestani SK. Monitoring ZEO apoptotic potential in 2D and 3D cell cultures and associated spectroscopic evidence on mode of interaction with DNA. Sci Rep. 2017;7:1\u201314. doi:10.1038/s41598-017-02633-z", "ArticleIdList": ["10.1038/s41598-017-02633-z", "PMC5451462", "28566685"]}, {"Citation": "Sajed H, Sahebkar A, Iranshahi M. Zataria multiflora Boiss. (Shirazi thyme)\u2014an ancient condiment with modern pharmaceutical uses. J Ethnopharmacol. 2013;145(3):686\u2013698. doi:10.1016/j.jep.2012.12.018", "ArticleIdList": ["10.1016/j.jep.2012.12.018", "23266333"]}, {"Citation": "Mahmoudvand H, Tavakoli Kareshk A, Nabi Moradi M, et al. Efficacy and safety of Zataria multiflora Boiss essential oil against acute toxoplasmosis in mice. Iran J Parasitol. 2020;15(1):22\u201330.", "ArticleIdList": ["PMC7244848", "32489372"]}, {"Citation": "Zomorodian K, Saharkhiz MJ, Rahimi MJ, et al. Chemical composition and antimicrobial activities of the essential oils from three ecotypes of Zataria multiflora. Pharmacogn Mag. 2011;7(25):53\u201359. doi:10.4103/0973-1296.75902", "ArticleIdList": ["10.4103/0973-1296.75902", "PMC3065158", "21472080"]}, {"Citation": "Sharififar F, Derakhshanfar A, Dehghan-Nudeh G, et al. In vivo antioxidant activity of Zataria multiflora Boiss essential oil. Pak J Pharm Sci. 2011;24(2):221\u2013225.", "ArticleIdList": ["21454174"]}, {"Citation": "Majlessi N, Choopani S, Kamalinejad M, Azizi Z. Amelioration of amyloid \u03b2-induced cognitive deficits by Zataria multiflora Boiss. essential oil in a rat model of Alzheimer\u2019s disease. CNS Neurosci Ther. 2012;18(4):295\u2013301. doi:10.1111/j.1755-5949.2011.00237.x", "ArticleIdList": ["10.1111/j.1755-5949.2011.00237.x", "PMC6493392", "22070531"]}, {"Citation": "Azadi M, Jamali T, Kianmehr Z, Kavoosi G, Ardestani SK. In-vitro (2D and 3D cultures) and in-vivo cytotoxic properties of Zataria multiflora essential oil (ZEO) emulsion in breast and cervical cancer cells along with the investigation of immunomodulatory potential. J Ethnopharmacol. 2020;257:112865. doi:10.1016/j.jep.2020.112865", "ArticleIdList": ["10.1016/j.jep.2020.112865", "32298750"]}, {"Citation": "Salehi F, Jamali T, Kavoosi G, Ardestani SK, Vahdati SN. Stabilization of Zataria essential oil with pectin-based nanoemulsion for enhanced cytotoxicity in monolayer and spheroid drug-resistant breast cancer cell cultures and deciphering its binding mode with gDNA. Int J Biol Macromol. 2020;164:3645\u20133655. doi:10.1016/j.ijbiomac.2020.08.084", "ArticleIdList": ["10.1016/j.ijbiomac.2020.08.084", "32795576"]}, {"Citation": "Metwally AA, El-Ahmady SH, Hathout RM. Selecting optimum protein nano-carriers for natural polyphenols using chemoinformatics tools. Phytomedicine. 2016;23(14):1764\u20131770. doi:10.1016/j.phymed.2016.10.020", "ArticleIdList": ["10.1016/j.phymed.2016.10.020", "27912878"]}, {"Citation": "Bharali DJ, Siddiqui IA, Adhami VM, et al. Nanoparticle delivery of natural products in the prevention and treatment of cancers: current status and future prospects. Cancers (Basel). 2011;3(4):4024\u20134045. doi:10.3390/cancers3044024", "ArticleIdList": ["10.3390/cancers3044024", "PMC3763408", "24213123"]}, {"Citation": "Atun S, Aznam N, Arianingrum R, Niwa M. Balanocarpol and heimiol A, two resveratrols dimer from stem bark Hopea mengarawan (Dipterocarpaceae). Indones J Chem. 2006;6(1):75\u201378. doi:10.22146/ijc.21777", "ArticleIdList": ["10.22146/ijc.21777"]}, {"Citation": "Lim KG, Gray AI, Pyne S, Pyne NJ. Resveratrol dimers are novel sphingosine kinase 1 inhibitors and affect sphingosine kinase 1 expression and cancer cell growth and survival. Br J Pharmacol. 2012;166(5):1605\u20131616. doi:10.1111/j.1476-5381.2012.01862.x", "ArticleIdList": ["10.1111/j.1476-5381.2012.01862.x", "PMC3419905", "22251058"]}, {"Citation": "Obeid MA, Gany SAS, Gray AI, Young L, Igoli JO, Ferro VA. Niosome-encapsulated balanocarpol: compound isolation, characterisation, and cytotoxicity evaluation against human breast and ovarian cancer cell lines. Nanotechnology. 2020;31(19):195101. doi:10.1088/1361-6528/ab6d9c", "ArticleIdList": ["10.1088/1361-6528/ab6d9c", "31958777"]}, {"Citation": "Alshaker H, Thrower H, Pchejetski D. Sphingosine kinase 1 in breast cancer-a new molecular marker and a therapy target. Front Oncol. 2020;10:289. doi:10.3389/fonc.2020.00289", "ArticleIdList": ["10.3389/fonc.2020.00289", "PMC7098968", "32266132"]}, {"Citation": "Heffernan-Stroud LA, Obeid LM. Sphingosine kinase 1 in cancer. Adv Cancer Res. 2017;117:201\u2013235. doi:10.1016/B978-0-12-394274-6.00007-8", "ArticleIdList": ["10.1016/B978-0-12-394274-6.00007-8", "PMC5491387", "23290781"]}, {"Citation": "Tuli HS, Sandhu SS, Sharma AK. Pharmacological and therapeutic potential of Cordyceps with special reference to Cordycepin. 3 Biotech. 2014;4(1):1\u201312. doi:10.1007/s13205-013-0121-9", "ArticleIdList": ["10.1007/s13205-013-0121-9", "PMC3909570", "28324458"]}, {"Citation": "Ashraf SA, Elkhalifa AEO, Siddiqui AJ, et al. Cordycepin for health and wellbeing: a potent bioactive metabolite of an entomopathogenic medicinal fungus Cordyceps with its nutraceutical and therapeutic potential. Molecules. 2020;25(12):2735. doi:10.3390/molecules25122735", "ArticleIdList": ["10.3390/molecules25122735", "PMC7356751", "32545666"]}, {"Citation": "Choi S, Lim MH, Kim KM, Jeon BH, Song WO, Kim TW. Cordycepin-induced apoptosis and autophagy in breast cancer cells are independent of the estrogen receptor. Toxicol Appl Pharmacol. 2011;257(2):165\u2013173. doi:10.1016/j.taap.2011.08.030", "ArticleIdList": ["10.1016/j.taap.2011.08.030", "21933677"]}, {"Citation": "Lee D, Lee WY, Jung K, et al. The inhibitory effect of cordycepin on the proliferation of MCF-7 breast cancer cells, and its mechanism: an investigation using network pharmacology-based analysis. Biomolecules. 2019;9(9):414. doi:10.3390/biom9090414", "ArticleIdList": ["10.3390/biom9090414", "PMC6770402", "31454995"]}, {"Citation": "Lee HJ, Burger P, Vogel M, Friese K, Br\u00fcning A. The nucleoside antagonist cordycepin causes DNA double strand breaks in breast cancer cells. Invest New Drugs. 2012;30(5):1917\u20131925. doi:10.1007/s10637-012-9859-x", "ArticleIdList": ["10.1007/s10637-012-9859-x", "22821173"]}, {"Citation": "Liu C, Qi M, Li L, Yuan Y, Wu X, Fu J. Natural cordycepin induces apoptosis and suppresses metastasis in breast cancer cells by inhibiting the Hedgehog pathway. Food Funct. 2020;11(3):2107\u20132116. doi:10.1039/c9fo02879j", "ArticleIdList": ["10.1039/c9fo02879j", "32163051"]}, {"Citation": "Wang D, Zhang Y, Lu J, et al. Cordycepin, a natural antineoplastic agent, induces apoptosis of breast cancer cells via caspase-dependent pathways. Nat Prod Commun. 2016;11(1):63\u201368. doi:10.1177/1934578X1601100119", "ArticleIdList": ["10.1177/1934578X1601100119", "26996021"]}, {"Citation": "Jiang Q, Lou Z, Wang H, Chen C. Antimicrobial effect and proposed action mechanism of cordycepin against Escherichia coli and Bacillus subtilis. J Microbiol. 2019;57(4):288\u2013297. doi:10.1007/s12275-019-8113-z", "ArticleIdList": ["10.1007/s12275-019-8113-z", "30929229"]}, {"Citation": "Choi YH, Kim GY, Lee HH. Anti-inflammatory effects of cordycepin in lipopolysaccharide-stimulated RAW 264.7 macrophages through Toll-like receptor 4-mediated suppression of mitogen-activated protein kinases and NF-\u03baB signaling pathways. Drug Des Devel Ther. 2014;8:1941\u20131953. doi:10.2147/DDDT.S71957", "ArticleIdList": ["10.2147/DDDT.S71957", "PMC4206205", "25342887"]}, {"Citation": "Ashraf S, Radhi M, Gowler P, et al. The polyadenylation inhibitor cordycepin reduces pain, inflammation and joint pathology in rodent models of osteoarthritis. Sci Rep. 2019;9:1\u201317. doi:10.1038/s41598-019-41140-1", "ArticleIdList": ["10.1038/s41598-019-41140-1", "PMC6423048", "30886197"]}, {"Citation": "Ma L, Zhang S, Du M. Cordycepin from Cordyceps militaris prevents hyperglycemia in alloxan-induced diabetic mice. Nutr Res. 2015;35(5):431\u2013439. doi:10.1016/j.nutres.2015.04.011", "ArticleIdList": ["10.1016/j.nutres.2015.04.011", "25940982"]}, {"Citation": "Gao J, Lian ZQ, Zhu P, Zhu HB. Lipid-lowering effect of cordycepin (3\u02b9-deoxyadenosine) from Cordyceps militaris on hyperlipidemic hamsters and rats. Acta Pharm Sin. 2011;46(6):669\u2013676.", "ArticleIdList": ["21882527"]}, {"Citation": "Cho HJ, Cho JY, Rhee MH, Kim HS, Lee HS, Park HJ. Inhibitory effects of cordycepin (3\u02b9-deoxyadenosine), a component of Cordyceps militaris, on human platelet aggregation induced by thapsigargin. J Microbiol Biotechnol. 2007;17(7):1134\u20131138.", "ArticleIdList": ["18051324"]}, {"Citation": "Qin P, Li X, Yang H, Wang ZY, Lu D. Therapeutic potential and biological applications of cordycepin and metabolic mechanisms in cordycepin-producing fungi. Molecules. 2019;24(12):2231. doi:10.3390/molecules24122231", "ArticleIdList": ["10.3390/molecules24122231", "PMC6632035", "31207985"]}, {"Citation": "Marslin G, Khandelwal V, Franklin G. Cordycepin nanoencapsulated in poly(lactic-co-glycolic acid) exhibits better cytotoxicity and lower hemotoxicity than free drug. Nanotechnol Sci Appl. 2020;13:37\u201345. doi:10.2147/NSA.S254770", "ArticleIdList": ["10.2147/NSA.S254770", "PMC7305845", "32606622"]}, {"Citation": "Hewlings SJ, Kalman DS. Curcumin: a Review of Its\u2019 Effects on Human Health. Foods. 2017;6(10):92. doi:10.3390/foods6100092", "ArticleIdList": ["10.3390/foods6100092", "PMC5664031", "29065496"]}, {"Citation": "Mishra A, Kumar R, Tyagi A, et al. Curcumin modulates cellular AP-1, NF-kB, and HPV16 E6 proteins in oral cancer. Ecancermedicalscience. 2015;9:525. doi:10.3332/ecancer.2015.525", "ArticleIdList": ["10.3332/ecancer.2015.525", "PMC4407748", "25932049"]}, {"Citation": "Sun SH, Huang HC, Huang C, Lin JK. Cycle arrest and apoptosis in MDA-MB-231/Her2 cells induced by curcumin. Eur J Pharmacol. 2012;690(1\u20133):22\u201330. doi:10.1016/j.ejphar.2012.05.036", "ArticleIdList": ["10.1016/j.ejphar.2012.05.036", "22705896"]}, {"Citation": "Bimonte S, Barbieri A, Palma G, et al. Dissecting the role of curcumin in tumour growth and angiogenesis in mouse model of human breast cancer. Biomed Res Int. 2015;2015:878134. doi:10.1155/2015/878134", "ArticleIdList": ["10.1155/2015/878134", "PMC4386568", "25879038"]}, {"Citation": "Hu S, Xu Y, Meng L, Huang L, Sun H. Curcumin inhibits proliferation and promotes apoptosis of breast cancer cells. Exp Ther Med. 2018;16(2):1266\u20131272. doi:10.3892/etm.2018.6345", "ArticleIdList": ["10.3892/etm.2018.6345", "PMC6090267", "30116377"]}, {"Citation": "Prasad CP, Rath G, Mathur S, Bhatnagar D, Ralhan R. Potent growth suppressive activity of curcumin in human breast cancer cells: modulation of Wnt/beta-catenin signaling. Chem Biol Interact. 2009;181(2):263\u2013271. doi:10.1016/j.cbi.2009.06.012", "ArticleIdList": ["10.1016/j.cbi.2009.06.012", "19573523"]}, {"Citation": "He ZY, Shi CB, Wen H, Li FL, Wang BL, Wang J. Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin. Cancer Invest. 2011;29(3):208\u2013213. doi:10.3109/07357907.2010.550592", "ArticleIdList": ["10.3109/07357907.2010.550592", "21314329"]}, {"Citation": "D\u00edaz Osterman CJ, Gonda A, Stiff T, et al. Curcumin induces pancreatic adenocarcinoma cell death via reduction of the inhibitors of apoptosis. Pancreas. 2017;45(1):101\u2013109. doi:10.1097/MPA.0000000000000411", "ArticleIdList": ["10.1097/MPA.0000000000000411", "PMC4679699", "26348467"]}, {"Citation": "Phillips JM, Clark C, Herman-Ferdinandez L, et al. Curcumin inhibits skin squamous cell carcinoma tumor growth in vivo. Otolaryngol Neck Surg. 2011;145(1):58\u201363. doi:10.1177/0194599811400711", "ArticleIdList": ["10.1177/0194599811400711", "21493306"]}, {"Citation": "LoTempio MM, Veena MS, Steele HL, et al. Curcumin suppresses growth of head and neck squamous cell carcinoma. Clin Cancer Res. 2005;11(19 Pt 1):6994\u20137002. doi:10.1158/1078-0432.CCR-05-0301", "ArticleIdList": ["10.1158/1078-0432.CCR-05-0301", "16203793"]}, {"Citation": "Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807\u2013818. doi:10.1021/mp700113r", "ArticleIdList": ["10.1021/mp700113r", "17999464"]}, {"Citation": "Hassani A, Mahmood S, Enezei HH, et al. Formulation, characterization and biological activity screening of sodium alginate-gum arabic nanoparticles loaded with curcumin. Molecules. 2020;25(9):2244. doi:10.3390/molecules25092244", "ArticleIdList": ["10.3390/molecules25092244", "PMC7249151", "32397633"]}, {"Citation": "Farhangi B, Alizadeh AM, Khodayari H, et al. Protective effects of dendrosomal curcumin on an animal metastatic breast tumor. Eur J Pharmacol. 2015;758:188\u2013196. doi:10.1016/j.ejphar.2015.03.076", "ArticleIdList": ["10.1016/j.ejphar.2015.03.076", "25863259"]}, {"Citation": "Hasan M, Belhaj N, Benachour H, et al. Liposome encapsulation of curcumin: physico-chemical characterizations and effects on MCF7 cancer cell proliferation. Int J Pharm. 2014;461(1\u20132):519\u2013528. doi:10.1016/j.ijpharm.2013.12.007", "ArticleIdList": ["10.1016/j.ijpharm.2013.12.007", "24355620"]}, {"Citation": "Serini S, Fasano E, Piccioni E, Cittadini AR, Calviello G. Differential anti-cancer effects of purified EPA and DHA and possible mechanisms involved. Curr Med Chem. 2011;18(26):4065\u20134075. doi:10.2174/092986711796957310", "ArticleIdList": ["10.2174/092986711796957310", "21824086"]}, {"Citation": "Hasan M, Elkhoury K, Belhaj N, et al. Growth-inhibitory effect of chitosan-coated liposomes encapsulating curcumin on MCF-7 breast cancer cells. Mar Drugs. 2020;18(4):217. doi:10.3390/md18040217", "ArticleIdList": ["10.3390/md18040217", "PMC7230998", "32316578"]}, {"Citation": "Sarika PR, Nirmala RJ. Curcumin loaded gum arabic aldehyde-gelatin nanogels for breast cancer therapy. Mater Sci Eng C. 2016;65:331\u2013337. doi:10.1016/j.msec.2016.04.044", "ArticleIdList": ["10.1016/j.msec.2016.04.044", "27157759"]}, {"Citation": "Yu SR, Zhang XP, He ZM, Liu YH, Liu ZH. Effects of Ce on the short-term biocompatibility of Ti-Fe-Mo-Mn-Nb-Zr alloy for dental materials. J Mater Sci Mater Med. 2004;15(6):687\u2013691. doi:10.1023/b:jmsm.0000030210.83891.d4", "ArticleIdList": ["10.1023/b:jmsm.0000030210.83891.d4", "15346736"]}, {"Citation": "Hussein Y, Loutfy SA, Kamoun EA, El-Moslamy SH, Radwan EM, Elbehairi SEI. Enhanced anti-cancer activity by localized delivery of curcumin form PVA/CNCs hydrogel membranes: preparation and in vitro bioevaluation. Int J Biol Macromol. 2021;170:107\u2013122. doi:10.1016/j.ijbiomac.2020.12.133", "ArticleIdList": ["10.1016/j.ijbiomac.2020.12.133", "33358954"]}, {"Citation": "Bai F, Diao J, Wang Y, et al. A new water-soluble nanomicelle formed through self-assembly of pectin-curcumin conjugates: preparation, characterization, and anticancer activity evaluation. J Agric Food Chem. 2017;65(32):6840\u20136847. doi:10.1021/acs.jafc.7b02250", "ArticleIdList": ["10.1021/acs.jafc.7b02250", "28721737"]}, {"Citation": "Jithan AV, Madhavi K, Madhavi M, Prabhakar K. Preparation and characterization of albumin nanoparticles encapsulating curcumin intended for the treatment of breast cancer. Int J Pharm Investig. 2011;1(2):119\u2013125. doi:10.4103/2230-973X.82432", "ArticleIdList": ["10.4103/2230-973X.82432", "PMC3465130", "23071931"]}, {"Citation": "Khazaei Koohpar Z, Entezari M, Movafagh A, Hashemi M. Anticancer activity of curcumin on human breast adenocarcinoma: role of Mcl-1 gene. Iran J Cancer Prev. 2015;8(3):e2331. doi:10.17795/ijcp2331", "ArticleIdList": ["10.17795/ijcp2331", "PMC4581370", "26413251"]}, {"Citation": "Danafar H, Sharafi A, Askarlou S, Manjili HK. Preparation and characterization of PEGylated iron oxide-gold nanoparticles for delivery of sulforaphane and curcumin. Drug Res. 2017;67(12):698\u2013704. doi:10.1055/s-0043-115905", "ArticleIdList": ["10.1055/s-0043-115905", "28738425"]}, {"Citation": "Cheung A, Bax HJ, Josephs DH, et al. Targeting folate receptor alpha for cancer treatment. Oncotarget. 2016;7(32):52553\u201352574. doi:10.18632/oncotarget.9651", "ArticleIdList": ["10.18632/oncotarget.9651", "PMC5239573", "27248175"]}, {"Citation": "Wang J, Wang Y, Liu Q, et al. Rational design of multifunctional dendritic mesoporous silica nanoparticles to load curcumin and enhance efficacy for breast cancer therapy. ACS Appl Mater Interfaces. 2016;8(40):26511\u201326523. doi:10.1021/acsami.6b08400", "ArticleIdList": ["10.1021/acsami.6b08400", "27619078"]}, {"Citation": "Ansary J, Forbes-Hern\u00e1ndez TY, Gil E, et al. Potential health benefit of garlic based on human intervention studies: a brief overview. Antioxidants. 2020;9(7):619. doi:10.3390/antiox9070619", "ArticleIdList": ["10.3390/antiox9070619", "PMC7402177", "32679751"]}, {"Citation": "Dorrigiv M, Zareiyan A, Garlic HH. (Allium sativum) as an antidote or a protective agent against natural or chemical toxicities: a comprehensive update review. Phyther Res. 2020;34(8):1770\u20131797. doi:10.1002/ptr.6645", "ArticleIdList": ["10.1002/ptr.6645", "32068926"]}, {"Citation": "Shang A, Cao SY, Xu XY, et al. Bioactive compounds and biological functions of garlic (Allium sativum L.). Foods. 2019;8(7):246. doi:10.3390/foods8070246", "ArticleIdList": ["10.3390/foods8070246", "PMC6678835", "31284512"]}, {"Citation": "Altonsy MO, Habib TN, Andrews SC. Diallyl disulfide-induced apoptosis in a breast-cancer cell line (MCF-7) may be caused by inhibition of histone deacetylation. Nutr Cancer. 2012;64(8):1251\u20131260. doi:10.1080/01635581.2012.721156", "ArticleIdList": ["10.1080/01635581.2012.721156", "23163853"]}, {"Citation": "Huang J, Yang B, Xiang T, et al. Diallyl disulfide inhibits growth and metastatic potential of human triple-negative breast cancer cells through inactivation of the \u03b2-catenin signaling pathway. Mol Nutr Food Res. 2015;59(6):1063\u20131075. doi:10.1002/mnfr.201400668", "ArticleIdList": ["10.1002/mnfr.201400668", "25755089"]}, {"Citation": "Lei XY, Yao SQ, Zu XY, et al. Apoptosis induced by diallyl disulfide in human breast cancer cell line MCF-7. Acta Pharmacol Sin. 2008;29(10):1233\u20131239. doi:10.1111/j.1745-7254.2008.00851.x", "ArticleIdList": ["10.1111/j.1745-7254.2008.00851.x", "18817629"]}, {"Citation": "Xiao X, Chen B, Liu X, et al. Diallyl disulfide suppresses SRC/Ras/ERK signaling-mediated proliferation and metastasis in human breast cancer by up-regulating miR-34a. PLoS One. 2014;9(11):e112720. doi:10.1371/journal.pone.0112720", "ArticleIdList": ["10.1371/journal.pone.0112720", "PMC4232521", "25396727"]}, {"Citation": "Xiong T, Liu XW, Huang XL, et al. Tristetraprolin: a novel target of diallyl disulfide that inhibits the progression of breast cancer. Oncol Lett. 2018;15(5):7817\u20137827. doi:10.3892/ol.2018.8299", "ArticleIdList": ["10.3892/ol.2018.8299", "PMC5920483", "29725473"]}, {"Citation": "Jun Z, Suzuki M, Xiao J, et al. Comparative effects of natural and synthetic diallyl disulfide on apoptosis of human breast-cancer MCF-7 cells. Biotechnol Appl Biochem. 2009;52(Pt2):113\u2013119. doi:10.1042/BA20070242", "ArticleIdList": ["10.1042/BA20070242", "18289126"]}, {"Citation": "Talluri SV, Kuppusamy G, Karri VVSR, et al. Application of quality-by-design approach to optimize diallyl disulfide-loaded solid lipid nanoparticles. Artif Cells, Nanomedicine, Biotechnol. 2016;45(3):474\u2013488. doi:10.3109/21691401.2016.1173046", "ArticleIdList": ["10.3109/21691401.2016.1173046", "27112220"]}, {"Citation": "Schr\u00f6ter D, H\u00f6hn A. Role of advanced glycation end products in carcinogenesis and their therapeutic implications. Curr Pharm Des. 2019;24(44):261\u2013266. doi:10.2174/1381612825666190130145549", "ArticleIdList": ["10.2174/1381612825666190130145549", "PMC6635609", "30706806"]}, {"Citation": "Kwak T, Drews-Elger K, Ergonul A, et al. Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis. Oncogene. 2016;36(11):1559\u20131572. doi:10.1038/onc.2016.324", "ArticleIdList": ["10.1038/onc.2016.324", "27669433"]}, {"Citation": "Chacko SM, Thambi PT, Kuttan R, Nishigaki I. Beneficial effects of green tea: a literature review. Chin Med. 2010;5:1\u20139. doi:10.1186/1749-8546-5-13", "ArticleIdList": ["10.1186/1749-8546-5-13", "PMC2855614", "20370896"]}, {"Citation": "Nagle DG, Ferreira D, Zhou YD. Epigallocatechin-3-gallate (EGCG): chemical and biomedical perspectives. Phytochemistry. 2006;67(17):1849\u20131855. doi:10.1016/j.phytochem.2006.06.020", "ArticleIdList": ["10.1016/j.phytochem.2006.06.020", "PMC2903211", "16876833"]}, {"Citation": "Thangapazham RL, Passi N, Maheshwari RK. Green tea polyphenol and epigallocatechin gallate induce apoptosis and inhibit invasion in human breast cancer cells. Cancer Biol Ther. 2007;6(12):1938\u20131943. doi:10.4161/cbt.6.12.4974", "ArticleIdList": ["10.4161/cbt.6.12.4974", "18059161"]}, {"Citation": "Braicu C, Gherman CD, Irimie A, Berindan-Neagoe I. Epigallocatechin-3-Gallate (EGCG) inhibits cell proliferation and migratory behaviour of triple negative breast cancer cells. J Nanosci Nanotechnol. 2013;13(1):632\u2013637. doi:10.1166/jnn.2013.6882", "ArticleIdList": ["10.1166/jnn.2013.6882", "23646788"]}, {"Citation": "Gu JW, Makey KL, Tucker KB, et al. EGCG, a major green tea catechin suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1\u03b1 and NF\u03baB, and VEGF expression. Vasc Cell. 2013;5(1):9. doi:10.1186/2045-824X-5-9", "ArticleIdList": ["10.1186/2045-824X-5-9", "PMC3649947", "23638734"]}, {"Citation": "Wei R, Mao L, Xu P, et al. Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models. Food Funct. 2018;9(11):5682\u20135696. doi:10.1039/c8fo01397g", "ArticleIdList": ["10.1039/c8fo01397g", "PMC7480214", "30310905"]}, {"Citation": "Zan L, Chen Q, Zhang L, Li X. Epigallocatechin gallate (EGCG) suppresses growth and tumorigenicity in breast cancer cells by downregulation of miR-25. Bioengineered. 2019;10(1):374\u2013382. doi:10.1080/21655979.2019.1657327", "ArticleIdList": ["10.1080/21655979.2019.1657327", "PMC6738446", "31431131"]}, {"Citation": "Meeran SM, Patel SN, Chan TH, Tollefsbol TO. A novel prodrug of epigallocatechin-3-gallate: differential epigenetic hTERT repression in human breast cancer cells. Cancer Prev Res. 2011;4(8):1243\u20131254. doi:10.1158/1940-6207.CAPR-11-0009", "ArticleIdList": ["10.1158/1940-6207.CAPR-11-0009", "PMC3128170", "21411498"]}, {"Citation": "Radhakrishnan R, Kulhari H, Pooja D, et al. Encapsulation of biophenolic phytochemical EGCG within lipid nanoparticles enhances its stability and cytotoxicity against cancer. Chem Phys Lipids. 2016;198:51\u201360. doi:10.1016/j.chemphyslip.2016.05.006", "ArticleIdList": ["10.1016/j.chemphyslip.2016.05.006", "27234272"]}, {"Citation": "Moreno P, Ramos-\u00e1lvarez I, Moody TW, Jensen RT. Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment. Expert Opin Ther Targets. 2016;20(9):1055\u20131073. doi:10.1517/14728222.2016.1164694", "ArticleIdList": ["10.1517/14728222.2016.1164694", "PMC5067074", "26981612"]}, {"Citation": "Radhakrishnan R, Pooja D, Kulhari H, et al. Bombesin conjugated solid lipid nanoparticles for improved delivery of epigallocatechin gallate for breast cancer treatment. Chem Phys Lipids. 2019;224:104770. doi:10.1016/j.chemphyslip.2019.04.005", "ArticleIdList": ["10.1016/j.chemphyslip.2019.04.005", "30965023"]}, {"Citation": "Kahkeshani N, Farzaei F, Fotouhi M, et al. Pharmacological effects of gallic acid in health and diseases: a mechanistic review. Iran J Basic Med Sci. 2019;22(3):225\u2013237. doi:10.22038/ijbms.2019.32806.7897", "ArticleIdList": ["10.22038/ijbms.2019.32806.7897", "PMC6528712", "31156781"]}, {"Citation": "Rezaei-Seresht H, Cheshomi H, Falanji F, Movahedi-Motlagh F, Hashemian M, Mireskandari E. Cytotoxic activity of caffeic acid and gallic acid against MCF-7 human breast cancer cells: an in silico and in vitro study. Avicenna J Phytomed. 2019;9(6):574\u2013586. doi:10.22038/AJP.2019.13475", "ArticleIdList": ["10.22038/AJP.2019.13475", "PMC6823530", "31763216"]}, {"Citation": "Lee HL, Lin CS, Kao SH, Chou MC. Gallic acid induces G1 phase arrest and apoptosis of triple-negative breast cancer cell MDA-MB-231 via p38 mitogen-activated protein kinase/p21/p27 axis. Anticancer Drugs. 2017;28(10):1150\u20131156. doi:10.1097/CAD.0000000000000565", "ArticleIdList": ["10.1097/CAD.0000000000000565", "28938245"]}, {"Citation": "Hsu JD, Kao SH, Ou TT, Chen YJ, Li YJ, Wang CJ. Gallic acid induces G2/M phase arrest of breast cancer cell MCF-7 through stabilization of p27(Kip1) attributed to disruption of p27(Kip1)/Skp2 complex. J Agric Food Chem. 2011;59(5):1996\u20132003. doi:10.1021/jf103656v", "ArticleIdList": ["10.1021/jf103656v", "21299246"]}, {"Citation": "Nowakowska A, Tarasiuk J. Comparative effects of selected plant polyphenols, gallic acid and epigallocatechin gallate, on matrix metalloproteinases activity in multidrug resistant MCF7/DOX breast cancer cells. Acta Biochim Pol. 2016;63(3):571\u2013575. doi:10.18388/abp.2016_1256", "ArticleIdList": ["10.18388/abp.2016_1256", "27231728"]}, {"Citation": "Garc\u00eda-Rivera D, Delgado R, Bougarne N, Haegeman G, Berghe WV. Gallic acid indanone and mangiferin xanthone are strong determinants of immunosuppressive anti-tumour effects of Mangifera indica L. bark in MDA-MB231 breast cancer cells. Cancer Lett. 2011;305(1):21\u201331. doi:10.1016/j.canlet.2011.02.011", "ArticleIdList": ["10.1016/j.canlet.2011.02.011", "21420233"]}, {"Citation": "BenSaad LA, Kim KH, Quah CC, Kim WR, Shahimi M. Anti-inflammatory potential of ellagic acid, gallic acid and punicalagin A&B isolated from Punica granatum. BMC Complement Altern Med. 2017;17:1\u201310. doi:10.1186/s12906-017-1555-0", "ArticleIdList": ["10.1186/s12906-017-1555-0", "PMC5237561", "28088220"]}, {"Citation": "Lu J, Wang Z, Ren M, et al. Antibacterial effect of gallic acid against Aeromonas hydrophila and Aeromonas sobria through damaging membrane integrity. Curr Pharm Biotechnol. 2016;17(13):1153\u20131158. doi:10.2174/1389201017666161022235759", "ArticleIdList": ["10.2174/1389201017666161022235759", "27774889"]}, {"Citation": "Asnaashari M, Farhoosh R, Sharif A. Antioxidant activity of gallic acid and methyl gallate in triacylglycerols of Kilka fish oil and its oil-in-water emulsion. Food Chem. 2014;159:439\u2013444. doi:10.1016/j.foodchem.2014.03.038", "ArticleIdList": ["10.1016/j.foodchem.2014.03.038", "24767079"]}, {"Citation": "Priscilla DH, Prince PS. Cardioprotective effect of gallic acid on cardiac troponin-T, cardiac marker enzymes, lipid peroxidation products and antioxidants in experimentally induced myocardial infarction in Wistar rats. Chem Biol Interact. 2009;179(2\u20133):118\u2013124. doi:10.1016/j.cbi.2008.12.012", "ArticleIdList": ["10.1016/j.cbi.2008.12.012", "19146839"]}, {"Citation": "Zhou D, Yang Q, Tian T, et al. Gastroprotective effect of gallic acid against ethanol-induced gastric ulcer in rats: involvement of the Nrf2/HO-1 signaling and anti-apoptosis role. Biomed Pharmacother. 2020;126:110075. doi:10.1016/j.biopha.2020.110075", "ArticleIdList": ["10.1016/j.biopha.2020.110075", "32179202"]}, {"Citation": "Maya S, Prakash T, Madhu K. Assessment of neuroprotective effects of gallic acid against glutamate-induced neurotoxicity in primary rat cortex neuronal culture. Neurochem Int. 2018;121:50\u201358. doi:10.1016/j.neuint.2018.10.011", "ArticleIdList": ["10.1016/j.neuint.2018.10.011", "30339985"]}, {"Citation": "Hassani A, Azarian MMS, Ibrahim WN, Hussain SA. Preparation, characterization and therapeutic properties of gum arabic-stabilized gallic acid nanoparticles. Sci Rep. 2020;10(1):17808. doi:10.1038/s41598-020-71175-8", "ArticleIdList": ["10.1038/s41598-020-71175-8", "PMC7576211", "33082415"]}, {"Citation": "Kaddam L, Fadl-Elmula I, Eisawi OA, et al. Gum Arabic as novel anti-oxidant agent in sickle cell anemia, phase II trial. BMC Hematol. 2017;17:1\u20136. doi:10.1186/s12878-017-0075-y", "ArticleIdList": ["10.1186/s12878-017-0075-y", "PMC5356407", "28331623"]}, {"Citation": "Nogueira V, Hay N. Molecular pathways: reactive oxygen species homeostasis in cancer cells and implications for cancer therapy. Clin Cancer Res. 2013;19(16):4309\u20134314. doi:10.1158/1078-0432.CCR-12-1424", "ArticleIdList": ["10.1158/1078-0432.CCR-12-1424", "PMC3933310", "23719265"]}, {"Citation": "Liou GY, Storz P. Reactive oxygen species in cancer. Free Radic Res. 2010;44(5):479\u2013496. doi:10.3109/10715761003667554", "ArticleIdList": ["10.3109/10715761003667554", "PMC3880197", "20370557"]}, {"Citation": "Nourazarian AR, Kangari P, Salmaninejad A. Roles of oxidative stress in the development and progression of breast cancer. Asian Pacific J Cancer Prev. 2014;15(12):4745\u20134751. doi:10.7314/apjcp.2014.15.12.4745", "ArticleIdList": ["10.7314/apjcp.2014.15.12.4745", "24998536"]}, {"Citation": "Pan L, Duan Y, Ma F, Lou L. Punicalagin inhibits the viability, migration, invasion, and EMT by regulating GOLPH3 in breast cancer cells. J Recept Signal Transduct. 2020;40(2):173\u2013180. doi:10.1080/10799893.2020.1719152", "ArticleIdList": ["10.1080/10799893.2020.1719152", "32024401"]}, {"Citation": "Aqil F, Munagala R, Vadhanam MV, et al. Anti-proliferative activity and protection against oxidative DNA damage by punicalagin isolated from pomegranate husk. Food Res Int. 2012;49(1):345\u2013353. doi:10.1016/j.foodres.2012.07.059", "ArticleIdList": ["10.1016/j.foodres.2012.07.059", "PMC3593254", "23493479"]}, {"Citation": "Kawabata K, Yoshioka Y, Terao J. Role of intestinal microbiota in the bioavailability and physiological functions of dietary polyphenols. Molecules. 2019;24(2):370. doi:10.3390/molecules24020370", "ArticleIdList": ["10.3390/molecules24020370", "PMC6359708", "30669635"]}, {"Citation": "Larrosa M, Tom\u00e1s-Barber\u00e1n FA, Esp\u00edn JC. The dietary hydrolysable tannin punicalagin releases ellagic acid that induces apoptosis in human colon adenocarcinoma Caco-2 cells by using the mitochondrial pathway. J Nutr Biochem. 2006;17(9):611\u2013625. doi:10.1016/j.jnutbio.2005.09.004", "ArticleIdList": ["10.1016/j.jnutbio.2005.09.004", "16426830"]}, {"Citation": "Wang N, Wang ZY, Mo SL, et al. Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer. Breast Cancer Res Treat. 2012;134(3):943\u2013955. doi:10.1007/s10549-012-1977-9", "ArticleIdList": ["10.1007/s10549-012-1977-9", "PMC3409373", "22350787"]}, {"Citation": "Chen HS, Bai MH, Zhang T, Li GD, Liu M. Ellagic acid induces cell cycle arrest and apoptosis through TGF-\u03b2/Smad3 signaling pathway in human breast cancer MCF-7 cells. Int J Oncol. 2015;46(4):1730\u20131738. doi:10.3892/ijo.2015.2870", "ArticleIdList": ["10.3892/ijo.2015.2870", "25647396"]}, {"Citation": "Wang N, Wang Q, Tang H, et al. Direct inhibition of ACTN4 by ellagic acid limits breast cancer metastasis via regulation of \u03b2-catenin stabilization in cancer stem cells. J Exp Clin Cancer Res. 2017;36(1):172. doi:10.1186/s13046-017-0635-9", "ArticleIdList": ["10.1186/s13046-017-0635-9", "PMC5712102", "29197410"]}, {"Citation": "Yousuf M, Shamsi A, Khan P, et al. Ellagic acid controls cell proliferation and induces apoptosis in breast cancer cells via inhibition of cyclin-dependent kinase 6. Int J Mol Sci. 2020;21(10):3526. doi:10.3390/ijms21103526", "ArticleIdList": ["10.3390/ijms21103526", "PMC7278979", "32429317"]}, {"Citation": "Long J, Guo Y, Yang J, et al. Bioavailability and bioactivity of free ellagic acid compared to pomegranate juice. Food Funct. 2019;10(10):6582\u20136588. doi:10.1039/c9fo01683j", "ArticleIdList": ["10.1039/c9fo01683j", "31552981"]}, {"Citation": "Seeram NP, Henning SM, Zhang Y, Suchard M, Li Z, Heber D. Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. J Nutr. 2006;136(10):2481\u20132485. doi:10.1093/jn/136.10.2481", "ArticleIdList": ["10.1093/jn/136.10.2481", "16988113"]}, {"Citation": "Bayat Mokhtari R, Baluch N, Homayouni TS, et al. The role of Sulforaphane in cancer chemoprevention and health benefits: a mini-review. J Cell Commun Signal. 2018;12(1):91\u2013101. doi:10.1007/s12079-017-0401-y", "ArticleIdList": ["10.1007/s12079-017-0401-y", "PMC5842175", "28735362"]}, {"Citation": "Sikdar S, Papadopoulou M, Dubois J. What do we know about sulforaphane protection against photoaging? J Cosmet Dermatol. 2016;15(1):72\u201377. doi:10.1111/jocd.12176", "ArticleIdList": ["10.1111/jocd.12176", "26799467"]}, {"Citation": "Qi T, Xu F, Yan X, Li S, Li H. Sulforaphane exerts anti-inflammatory effects against lipopolysaccharide-induced acute lung injury in mice through the Nrf2/ARE pathway. Int J Mol Med. 2016;37(1):182\u2013188. doi:10.3892/ijmm.2015.2396", "ArticleIdList": ["10.3892/ijmm.2015.2396", "26531002"]}, {"Citation": "Johansson NL, Pavia CS, Chiao JW. Growth inhibition of a spectrum of bacterial and fungal pathogens by sulforaphane, an isothiocyanate product found in broccoli and other cruciferous vegetables. Planta Med. 2008;74(7):747\u2013750. doi:10.1055/s-2008-1074520", "ArticleIdList": ["10.1055/s-2008-1074520", "18484523"]}, {"Citation": "Fahey JW, Talalay P. Antioxidant functions of sulforaphane: a potent inducer of Phase II detoxication enzymes. Food Chem Toxicol. 1999;37(9\u201310):973\u2013979. doi:10.1016/s0278-6915(99)00082-4", "ArticleIdList": ["10.1016/s0278-6915(99)00082-4", "10541453"]}, {"Citation": "Axelsson AS, Tubbs E, Mecham B, et al. Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes. Sci Transl Med. 2017;9(394):eaah4477. doi:10.1126/scitranslmed.aah4477", "ArticleIdList": ["10.1126/scitranslmed.aah4477", "28615356"]}, {"Citation": "Morroni F, Tarozzi A, Sita G, et al. Neuroprotective effect of sulforaphane in 6-hydroxydopamine-lesioned mouse model of Parkinson\u2019s disease. Neurotoxicology. 2013;36:63\u201371. doi:10.1016/j.neuro.2013.03.004", "ArticleIdList": ["10.1016/j.neuro.2013.03.004", "23518299"]}, {"Citation": "Sarkar R, Mukherjee S, Biswas J, Roy M. Sulphoraphane, a naturally occurring isothiocyanate induces apoptosis in breast cancer cells by targeting heat shock proteins. Biochem Biophys Res Commun. 2012;427(1):80\u201385. doi:10.1016/j.bbrc.2012.09.006", "ArticleIdList": ["10.1016/j.bbrc.2012.09.006", "22975350"]}, {"Citation": "Pawlik A, Wiczk A, Kaczy\u0144ska A, Antosiewicz J, Herman-Antosiewicz A. Sulforaphane inhibits growth of phenotypically different breast cancer cells. Eur J Nutr. 2013;52(8):1949\u20131958. doi:10.1007/s00394-013-0499-5", "ArticleIdList": ["10.1007/s00394-013-0499-5", "PMC3832756", "23389114"]}, {"Citation": "Cao C, Wu H, Vasilatos SN, et al. HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells. Int J Cancer. 2018;143(6):1388\u20131401. doi:10.1002/ijc.31419", "ArticleIdList": ["10.1002/ijc.31419", "PMC6105499", "29633255"]}, {"Citation": "Hunakova L, Sedlakova O, Cholujova D, Gronesova P, Duraj J, Sedlak J. Modulation of markers associated with aggressive phenotype in MDA-MB-231 breast carcinoma cells by sulforaphane. Neoplasma. 2009;56(6):548\u2013556. doi:10.4149/neo_2009_06_548", "ArticleIdList": ["10.4149/neo_2009_06_548", "19728765"]}, {"Citation": "Zambrano V, Bustos R, Mahn A. Insights about stabilization of sulforaphane through microencapsulation. Heliyon. 2019;5(11):e02951. doi:10.1016/j.heliyon.2019.e02951", "ArticleIdList": ["10.1016/j.heliyon.2019.e02951", "PMC6895643", "31844781"]}, {"Citation": "Li J, Kataoka K. Chemo-physical strategies to advance the in vivo functionality of targeted nanomedicine: the next generation. J Am Chem Soc. 2021;143(2):538\u2013559. doi:10.1021/jacs.0c09029", "ArticleIdList": ["10.1021/jacs.0c09029", "33370092"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "8", "Day": "26"}, {"Year": "2021", "Month": "11", "Day": "10"}, {"Year": "2021", "Month": "12", "Day": "9", "Hour": "6", "Minute": "57"}, {"Year": "2021", "Month": "12", "Day": "10", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "12", "Day": "15", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "12", "Day": "2"}], "PublicationStatus": "epublish", "ArticleIdList": ["34880614", "PMC8648329", "10.2147/IJN.S328135", "328135"]}}], "PubmedBookArticle": []}